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2. Overview and Summary 
 
Approximately 10-15% of all ischaemic strokes are caused by atherosclerotic stenosis of the carotid 
artery. Conventionally, carotid stenosis was treated by surgical removal of the atherosclerotic plaque 
(carotid endarterectomy). Since the introduction of carotid artery stenting as a less invasive treatment 
alternative almost 20 years ago, the choice of the optimal treatment for the individual patient with 
carotid stenosis has remained controversial. This PhD thesis consisted of three individual projects and 
aimed to enable personalised treatment decisions for individual patients with carotid disease and 
explore parameters specifically linked to the mechanisms of stroke occurring as a complication of both 
revascularisation procedures. 
The first project consisted of a systematic review and meta-analysis with the aim to compare short-
term risks and long-term effects on stroke prevention between carotid stenting and endarterectomy 
in patients with symptomatic or asymptomatic carotid stenosis. To this end, we performed a 
systematic Cochrane Review of all published randomised trials comparing carotid stenting versus 
endarterectomy to obtain precise overall estimates of procedural risks and long-term stroke 
recurrence rates. We found that in patients with symptomatic carotid stenosis, stenting and 
endarterectomy are equally effective in preventing recurrent stroke in the long-term, while stenting is 
associated with a higher risk of procedure related stroke or death. In patients with asymptomatic 
carotid stenosis, there may be a small increase in the risk of procedure related stroke or death 
associated with stenting. However, more data from randomised trials are needed. Concerning the 
durability of carotid stenting in the long-term, only limited data are currently available for 
asymptomatic patients and the existing evidence does not yet allow any firm conclusions.  
The second project comprised the systematic assessment of the anatomy of all supra-aortic arteries 
and pre-defined stenosis characteristics in order to investigate the association between vascular 
anatomy and the occurrence of procedure-related cerebral ischaemia after carotid artery stenting or 
carotid endarterectomy in patients with symptomatic carotid stenosis. We identified complex vascular 
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anatomy as an important predictor for cerebral ischaemia during stenting, but not during 
endarterectomy.  
The third and fourth projects consisted of an individual patient data meta-analysis of four randomised 
clinical trials comparing carotid artery stenting versus endarterectomy for treatment of symptomatic 
carotid stenosis. This work resulted in two separate manuscripts. Within the first, we investigated 
whether the temporal distribution of stroke or death occurring within 30 days of treatment differed 
between the two procedures. In the second, we investigated if the procedural risks associated with 
carotid stenting and carotid endarterectomy within the examined trials had decreased over time. Our 
analysis revealed that the excess occurrence of stroke or death associated with stenting is limited to 
the day of treatment. In our analysis of temporal trends in procedure related risks, we were able to 
show that carotid revascularisation procedures became safer over time within the examined trials. This 
decline in risk was particularly apparent for endarterectomy.  
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3. List of Abbreviations 
 
ACST-2 2nd Asymptomatic Carotid Surgery Trial 
ACT-1 
Randomised Trial of Stent versus Surgery for 
Asymptomatic Carotid Stenosis 
ACTRIS 
Endarterectomy Combined with Optimal 
Medical Therapy (OMT) vs OMT Alone in 
Patients With Asymptomatic Severe 
Atherosclerotic Carotid Artery Stenosis at 
Higher-than-average Risk of Ipsilateral Stroke 
CAS Carotid Artery Stening 
CCA Common Carotid Artery  
CEA Carotid Endarterectomy 
CE-MRA 
Contrast Enhanced Magnetic Resonance 
Angiography 
CI Confidence Interval 
CREST 
Carotid Revascularization Endarterectomy 
versus Stenting Trial 
CSTC Carotid Stenosis Trialists’ Collaboration 
CT Computed Tomography 
CTA Computed Tomography Angiography 
DSA Digital Subtraction Angiography 
DWI Diffusion Weighted Imaging 
ECA External Carotid Artery 
ECST European Carotid Surgery Trial 
ECST-2 2nd European Carotid Surgery Trial 
EVA-3S 
Endarterectomy Versus Angioplasty in patients 
with Symptomatic Severe Carotid Stenosis  
GLMM Generalised Linear Mixed-Effects Model 
ICA Internal Carotid Artery 
ICC Intraclass Correlation Coefficient 
ICSS International Carotid Stenting Study 
IPH Intra-Plaque Haemorrhage 
MRI Magnetic Resonance Imaging 
NASCET 
North American Symptomatic Carotid 
Endarterectomy Trial 
OR Odds Ratio 
QE Qualifying Event 
RCT Randomised Clinical Trial 
SPACE 
Stent-Protected Angioplasty versus Carotid 
Endarterectomy  
SPACE-2 
Stent-Protected Angioplasty versus Carotid 
Endarterectomy 2  
TIA Transient Ischaemic Attack 
TOF MRA Time of Flight Magnetic Resonance Angiography 
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4. Introduction 
 
4.1 Stroke and carotid disease  
 
Stroke is the leading cause of acquired disability in adult life and the second most common cause of 
death worldwide.1 Stroke is commonly defined as a rapidly evolving clinical syndrome consisting of 
signs and symptoms of focal neurological disturbance due to ischaemia or haemorrhage, lasting more 
than 24 hours.2 A transient ischaemic attack (TIA) on the other hand, has been recently defined as “a 
brief episode of neurologic dysfunction caused by focal brain or retinal ischaemia, with clinical 
symptoms typically lasting less than one hour, and without evidence of acute infarction” on imaging.3 
Diagnosis and early treatment of both stroke and TIA are of great importance to prevent disability, 
death and recurrent stroke. Atherosclerotic stenosis of the carotid artery is responsible for about 10 
to 15% of all ischaemic strokes.4 Carotid disease becomes more prevalent with increasing age, affecting 
approximately 7.5% of all men and 5.0% of all women over 80 years of age.5 The primary mechanism 
underlying cerebral ischaemia caused by carotid disease is plaque rupture and subsequent embolism 
to the brain. This has fostered the concept of the vulnerable or high-risk plaque, which is prone to 
rupture and cause ischaemic stroke.6, 7 In contrast to the high-risk plaque, the stable or low-risk plaque 
may remain inert over many years.  
4.2. Diagnostic work-up of carotid disease 
 
4.2.1. Digital subtraction angiography 
 
Initially, digital subtraction angiography (DSA) was routinely performed for diagnosis and grading of 
carotid stenosis. It was the primary method for determining the degree of stenosis in early randomised 
clinical trials (RCTs) establishing the benefit of carotid endarterectomy compared to medical therapy 
alone for treatment of symptomatic carotid stenosis.8 During DSA, a catheter is inserted in the femoral 
artery (or in some cases in the brachial artery) and advanced along the vascular tree to the carotid 
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arteries. A contrast medium is then injected which enables imaging of the lumen of all supra-aortic 
arteries including the cerebral arteries. However, due to its invasive nature, DSA carries a 4% risk of 
neurological complication (TIA or stroke), a 1% risk of disabling stroke, and a mortality rate of <0.1%.9 
Because of the risk of complications, other non-invasive imaging techniques to depict carotid stenosis 
have been developed (CT- and MR-angiography, ultrasound) and are now widely available.  Nowadays, 
DSA is reserved for the rare instances in which non-invasive imaging provides inconclusive or 
inconsistent information. 
4.2.2. CT- and MR-angiography  
 
Carotid stenosis can also be imaged by computed tomography (CT) or magnetic resonance (MR) based 
angiography. Important advantages of these imaging modalities include their non-invasive nature, 
their wide availability and the possibility to depict carotid plaque composition.  
CT-angiography (CTA) requires injection of a contrast medium to visualise the supra-aortic vessels and 
quantify carotid stenosis. Determining the degree of stenosis may be limited if heavy calcifications at 
the carotid bifurcation are present. Moreover, CTA has limited sensitivity in the distinction of moderate 
from severe carotid stenosis and the degree of stenosis might be underestimated using this non-
invasive imaging technique.10, 11  
MR based angiography is most commonly performed as contrast enhanced MRA (CE-MRA) although 
MR angiography without the application of a gadolinium-based contrast medium is also possible (time 
of flight MRA). CE-MRA has a higher sensitivity and specificity to accurately diagnose and grade carotid 
stenosis than time of flight (TOF) MRA.12 However, sensitivity for detection of moderate stenosis is 
limited with both TOF MRA and CE-MRA.13 An important advantage of MRA compared to CTA is the 
fact that it can be performed without the use of ionising radiation.  
Sensitivity and specificity of these non-invasive imaging techniques can be increased by combining 
different modalities, e.g. CE-MRA and duplex ultrasound.14 
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4.2.3. Duplex ultrasound 
 
Today, most neurovascular clinics rely strongly on Doppler and Duplex ultrasound for diagnostic work-
up of carotid stenosis. Ultrasound of the supra-aortic arteries carries no risk for the patient, as it is 
non-invasive and does not rely on ionising radiation. Additional benefits include low cost and wide 
availability. However, carotid ultrasound is dependent on the examiner’s experience and on the 
technical equipment used. Nevertheless, previous research demonstrated that contemporary 
ultrasound techniques using flow velocity measurements is highly accurate in detecting and 
quantifying carotid stenosis.15, 16 In addition, duplex ultrasound provides information on the 
haemodynamic relevance of carotid atherosclerosis and stenosis.  
4.2.4. Brain MRI as a surrogate outcome measure in carotid trials 
 
MRI is much more sensitive than clinical assessment in detecting ischaemic brain lesions. In a subset 
of 810 middle-aged persons without clinical or MRI evidence of stroke at baseline enrolled in the 
Atherosclerosis Risk in Communities Brain Magnetic Resonance Imaging Study, 20.2% of participants 
developed cerebral infarcts visible on MRI over a median of 10.5 years follow up.17 Silent ischaemic 
lesions on MRI are also found with increased frequency after minor stroke and TIA; in one study there 
was a 10% risk of new lesions on MRI, half of which were asymptomatic.18 Silent infarcts detected on 
MRI are also seen after carotid revascularisation procedures and have been proposed as a surrogate 
outcome measure in carotid trials.19-21 Thus, MRI detects cerebral infarcts in the absence of clinical 
signs and symptoms, both occurring as a complication of carotid revascularisation procedures and 
accumulating in patients treated medically for cerebrovascular atherosclerosis. These lesions appear 
to occur in at least twice the frequency as clinically manifest strokes. A main advantage of using MRI 
as an outcome measure is therefore that the power of the analysis is increased allowing to test a 
hypothesis in pilot studies with smaller sample sizes than in trials using clinical endpoints. In addition, 
MRI can be analysed blinded to the treatment modality, which is of relevance in randomised trials 
comparing carotid stenting versus carotid endarterectomy. 
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4.3. Treatment of carotid stenosis 
 
4.3.1. Medical therapy 
 
Medical therapy including the management of modifiable risk factors for cardiovascular disease plays 
an essential role in the care of patients with carotid disease. The main modifiable risk factors in 
cardiovascular disease include hypertension, diabetes mellitus, hyperlipidaemia, obesity, lack of 
sufficient exercise, and smoking.22 In addition, antiplatelet therapy is an important component of 
medical management in patients with carotid disease as it reduces the risk of embolization from the 
plaque.23 Recent studies have highlighted the importance of supporting the patient in achieving 
individually tailored lifestyle changes and adjusting medication to achieve personalised target values 
for blood pressure control and other vascular risk factors.24 
Lowering lipid levels has become an essential part of medical therapy in patients with carotid disease, 
especially after publication of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels 
(SPARCL) trial results. This randomised placebo controlled trial which compared high dose atorvastatin 
therapy versus placebo in patients with recent stroke or TIA, showed a 33% reduction in the risk of 
future stroke in patients with carotid atherosclerosis taking atorvastatin.25 
4.3.2. Carotid endarterectomy (CEA) 
 
For more than half a decade the standard treatment for carotid stenosis has been surgical removal of 
the atherosclerotic plaque (carotid endarterectomy). The first record of successful carotid 
endarterectomy was published in 1954 in the Lancet.26 In the years following this early description, the 
number of carotid operations performed increased tremendously and carotid endarterectomy (CEA) 
was widely adopted before reliable evidence on its benefit was available.27 Notably, CEA is not without 
risk and can cause death, stroke, myocardial infarction, and local complications such as haematoma 
and cranial nerve palsy.8 There are various surgical techniques in use. However, only limited evidence 
on their influence on the outcome of CEA is available. Conventionally, CEA is performed by longitudinal 
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arteriotomy. Alternatively, a transverse arteriotomy and re-implantation of the internal carotid artery 
(eversion endarterectomy) is also possible. However, high-quality evidence on the superiority of one 
surgical technique over the other is sparse and has been conflicting.28, 29 There is some evidence that 
the insertion of a synthetic or vein patch may reduce the risk of perioperative occlusion of the carotid 
artery and the occurrence of restenosis.30, 31 Patch angioplasty may also reduce the risk of peri-
operative stroke and mortality.31 However, the available evidence is poor and does not allow for a 
general recommendation of patch angioplasty.31 With regard to the use of shunts, which are applied 
as a temporary bypass to reduce the time during which blood flow is interrupted during CEA, only 
insufficient evidence is available to either support or refute its use.32  CEA can be performed under 
local or general anaesthesia, both of which show similar outcomes.33 
In order to justify performing CEA, the procedural risks must be outweighed by a long-term benefit in 
preventing stroke. In patients with recently symptomatic carotid stenosis, the benefit of CEA to 
prevent recurrent stroke was established in RCTs almost 30 years ago. In the 1980s and early 1990s, 
two large multicentre randomised controlled trials investigating the benefit of CEA versus medical 
therapy alone to prevent ipsilateral stroke in patients with symptomatic carotid stenosis were 
conducted: the North American Symptomatic Carotid Endarterectomy Trial (NASCET) and the 
European Carotid Surgery Trial (ECST).34, 35  
CEA was shown to be greatly beneficial in patients with severe carotid stenosis (≥ 70%) with an 
absolute reduction in ipsilateral stroke risk of 16% after 5 years.8, 36 However, in patients with moderate 
(50-69%) carotid stenosis the benefit of CEA was smaller and it remained unclear whether all patients 
in this group benefit from CEA.36, 37  
4.3.3. Carotid artery stenting (CAS) 
  
Towards the end of the 20th century, carotid artery stenting (CAS) was introduced as a less invasive 
alternative to CEA. This procedure consists of the insertion of an endovascular catheter, most 
commonly in the femoral artery, followed by dilation of the carotid stenosis with inflatable balloons 
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and self-expanding stent devices.38 Initially, percutaneous transluminal balloon angioplasty without 
the insertion of stent devices was performed. Later, stent devices specifically developed for the carotid 
arteries were introduced and primary stenting has since replaced balloon angioplasty alone as the 
endovascular treatment of choice.39 Today, various stent devices with different designs and 
configurations are in use. Previous studies demonstrated a higher risk of peri-procedural stroke in 
patients treated with open-cell stents, which is thought to be caused by incomplete coverage of the 
atherosclerotic lesion due to larger open areas between struts compared with closed-cell stents. 40-42 
Closed-cell devices on the other hand are more rigid and therefore less flexible.43 Consequently mesh 
covered stents have been developed to combine the lower risk of peri-procedural stroke associated 
with closed-cell stents and the flexibility of open-cell stents.44 
Potential advantages of CAS compared to CEA include the avoidance of a surgical incision in the neck 
with the risk of cranial and cutaneous nerve injury and reduction in the rate of general surgical 
complications such as myocardial infarction.45 However, CAS does not remove the atherosclerotic 
lesion at the carotid bifurcation and manipulation with the endovascular catheter in the vascular tree 
may dislodge emboli, which may cause distal embolization and stroke. Whether complex vascular 
anatomy increases the risk of dislodging emboli during catheter navigation, is currently unknown. In 
order to prevent procedure related stroke caused by dislodged emboli, cerebral protection systems 
have been introduced. The earliest of these devices were distal filters, which have to be advanced 
across the carotid stenosis first and deployed distally to capture any debris dislodged during the 
stenting procedure. However, whether these devices truly increase the safety of CAS remains 
controversial as they have to cross the lesion first, before they can be deployed and fulfil their intended 
purpose.46, 47 Moreover, distal filter devices cannot prevent emboli originating from the aortic arch 
occurring during catheter navigation in transfemoral CAS. Due to these issues, alternative protection 
systems, so called proximal protection devices or flow reversal protection, have been developed. These 
devices introduce flow reversal across the carotid bifurcation in order to prevent any emboli dislodged 
during the procedure to cause ischaemic stroke. In addition, alternative access routes to avoid 
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navigation of the aortic arch have been proposed. In recent years, direct catheterization of the 
common carotid artery (T-CAR) has been increasingly implemented with promising results, especially 
in conjunction with flow-reversal protection systems.48 However, high-quality evidence on the benefit 
of these novel protection systems is sparse and it remains to be shown whether these contemporary 
technologies improve procedural safety of CAS.  
Following the introduction of CAS as an alternative to CEA, several large RCTs comparing both 
treatment options in patients with symptomatic or asymptomatic carotid stenosis were conducted.49, 
50, 51, 52, 53 The identification and evaluation of these RCTs was part of the first project of this PhD thesis, 
in which we performed an update of a systematic Cochrane Review with the aim to identify all available 
randomised evidence comparing CAS versus CEA in patients with carotid stenosis. 
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5. Gaps in research and aims of this PhD thesis 
 
Atherosclerotic stenosis of the carotid artery is an important cause of ischaemic stroke. Following the 
introduction of CAS as a less invasive alternative to CEA, which allows revascularisation of the carotid 
stenosis by the insertion of self-expanding stents without the necessity of a surgical incision in the 
neck, the choice of the optimal treatment for the individual patient with carotid stenosis has remained 
controversial. 
1. In order to compare short-term risks and long-term effects on stroke prevention between CAS 
and CEA, we updated a systematic Cochrane Review last published in 2012 and included all 
randomised trials comparing CAS versus CEA to obtain precise overall estimates of procedural 
hazards and long-term stroke recurrence rates in patients with symptomatic or asymptomatic 
carotid stenosis (Project 1, section 6.1.). The previous update of this Review had shown that in 
patients with symptomatic carotid stenosis, CEA was associated with a lower risk of death or 
any stroke than CAS occurring between randomisation and 30 days after treatment.45 
However, only limited evidence had been available at the time on the comparative 
effectiveness of CAS and CEA in long-term prevention of stroke, and on their effect in patients 
with asymptomatic carotid stenosis. To investigate whether age or sex should inform the 
choice between CAS and CEA we additionally compared outcomes for men and women, and 
for younger and older patients, separately. 
2. Observational data suggests that anatomic features of the aortic arch and supra-aortic arteries 
may also increase the risk for procedure related cerebral ischaemia in CAS.54-57 However, 
randomised evidence on the impact of complex vascular anatomy on the risk of procedural 
cerebral ischaemia in CAS and CEA, and whether vascular anatomy might help inform the 
choice between CAS and CEA is sparse. In Project 2 (section 6.2.), we therefore aimed to 
systematically assess vascular anatomy and stenosis characteristics in patients with recently 
symptomatic carotid stenosis who were randomly assigned to CAS or CEA within an MRI-based 
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substudy of the International Carotid Stenting Study (ICSS). We sought to investigate the 
association between vascular anatomy as well as pre-defined stenosis characteristics and the 
risk of procedure-related cerebral ischaemia assessed on MRI after treatment. We 
hypothesized that difficult vascular anatomy would pose patients at greater risk of cerebral 
ischaemia during CAS, but not during CEA. 
3. To date, it has been unclear whether the excess risk of procedure related stroke associated 
with CAS is present throughout the 30-day peri-procedural period or whether it is limited to 
the day of treatment. Previous RCTs had been underpowered to investigate this question. In 
Project 3 (section 6.3.), we pooled data at individual patient level from four RCTs to investigate 
whether the risk of stroke or death occurring on the day of treatment versus between 1-30 
days thereafter differed between CAS and CEA. We additionally investigated, whether clinical 
risk factors for stroke or death differed between these two time periods. We hypothesized 
that the majority of strokes in both treatment groups would occur on the day of treatment, 
and that the increased risk of stroke or death associated with CAS would originate on the day 
of treatment. 
4. Since the introduction of CAS, technical advances and increasing operator experience might 
have led to a decrease in procedure related strokes. In Project 4 (section 6.4.), we aimed to 
analyse temporal changes in procedural stroke or death risks associated with CAS and CEA in 
the same pooled data set as in Project 3 (section 6.3.) of this thesis. We hypothesized that 
procedural risks associated with carotid revascularisation would have declined over time, and 
that procedural risks of CAS may have decreased more strongly than CEA risks due to technical 
development and increasing experience with this comparatively new procedure. 
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6. Projects 
 
6.1. Project 1 - Carotid artery stenting versus endarterectomy for treatment 
of carotid artery stenosis: Results from the updated systematic 
Cochrane Review 
 
Mandy D Müller MD1, Philippe A Lyrer MD1, Martin M Brown MD2, Leo H Bonati MD1,2 
 
Affiliations: 
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Published in Cochrane Database Systematic Reviews. 2020 Feb 25;2:CD000515. doi: 
10.1002/14651858.CD000515.pub5. Review. 
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Abstract 
 
Background - The previous update of this Review showed that in patients with symptomatic carotid 
stenosis, CEA was associated with a lower risk of death or any stroke occurring between randomisation 
and 30 days after treatment. However, only limited evidence was available on the long-term efficacy 
of CAS and on CAS in patients with asymptomatic carotid stenosis. Since the last update in 2012, 
several RCTs published results of extended follow-up periods and multiple trials comparing CAS versus 
CEA in patients with asymptomatic carotid stenosis were completed. We therefore aimed to update 
the previous version of this Review. 
Methods - We searched the Cochrane Stroke Group Trials Register (last searched August 2018) and 
the following databases: the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane 
Library 2010, Issue 4), MEDLINE (1950 to August 2018), EMBASE (1980 to August 2018) and Science 
Citation Index (1945 to August 2018). We also searched ongoing trials registers (August 2018), 
reference lists, and contacted researchers in the field. We included all randomised trials comparing 
carotid stenting (including balloon angioplasty or stenting) with endarterectomy or medical therapy 
for symptomatic or asymptomatic atherosclerotic carotid stenosis and calculated treatment effects as 
odds ratios (OR) and 95% confidence intervals (CI), with endarterectomy as the reference group. We 
quantified heterogeneity using the I² statistic. 
Main Results - We included 22 trials involving 9,753 patients. Eight trials (5,184 patients) compared 
CAS with CEA in patients with symptomatic carotid stenosis at standard surgical risk. In these patients, 
CAS was associated with a higher risk of death or any stroke (primary safety outcome) occurring 
between randomisation and 30 days after treatment than CEA (crude risks 7.2% vs. 4.4%; OR 1.70, 95% 
CI 1.31 to 2.19, P < 0.0001, I²=5%). The OR for the primary safety outcome was 1.11 (95% CI 0.74 to 
1.64) in patients < 70 years old and 2.23 (95% CI 1.61 to 3.08) in patients ≥ 70 years old (interaction P 
= 0.007). There was no significant difference in the risk of death or major or disabling stroke between 
CAS and CEA (crude risks 3.2% vs. 2.4%; OR 1.36, 95% CI 0.97, 1.91, P = 0.08; I² = 0%). CAS was 
associated with lower risks of myocardial infarction (OR 0.47, 95% CI 0.24 to 0.94, P = 0.03; I² = 0%), 
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cranial nerve palsy (OR 0.09, 95% CI 0.06 to 0.16, P < 0.00001; I² = 0%) and access site haematoma (OR 
0.32, 95% CI 0.15 to 0.68, P = 0.003; I² = 27%). The combination of death or any stroke up to 30 days 
after treatment or ipsilateral stroke during follow-up (the primary combined safety and efficacy 
outcome) favoured endarterectomy (OR 1.51, 95% CI 1.24 to 1.85, P < 0.0001; I² = 0%). However, the 
rate of ipsilateral stroke after the peri-procedural period did not differ between treatments (OR 1.05, 
95% CI 0.75 to 1.47, P = 0.77, I² =0%). 
Seven trials (3,378 patients) compared CAS with CEA in patients with asymptomatic carotid stenosis. 
In these patients, there was a statistically non-significant trend of a higher risk of the primary safety 
outcome (death or any stroke between randomisation and 30 days after treatment; crude risks 2.6% 
vs. 1.4%; OR 1.72, 95% CI 1.00 to 2.97, P = 0.05; I² = 0%) with CAS compared with CEA. The risk of death 
or any stroke up to 30 days after treatment or ipsilateral stroke during follow-up did not differ 
significantly between treatments (OR 1.27, 95% CI 0.87 to 1.84, P = 0.22; I² = 0%). 
Two trials (397 patients) compared CAS with CEA in patients with symptomatic or asymptomatic 
carotid stenosis considered to be at elevated surgical risk. In these patients, treatment effects on the 
primary safety outcome (death or any stroke between randomisation and 30 days after treatment; OR 
0.95, 95% CI 0.39 to 2.28, P = 0.90, I² = 0%) as well as the primary combined safety and efficacy outcome 
(death or any stroke up to 30 days after treatment or ipsilateral stroke during follow-up; OR 1.09, 95% 
CI 0.58 to 2.06, P = 0.79, I² = 0%) did not differ significantly between treatments. 
There was no significant difference in  risk of severe restenosis (≥70%) or occlusion after CAS compared 
with CEA (OR 1.26, 95% CI 0.79 to 2.00, P=0.33, I² =58%). Moderate or higher restenosis (≥50%) or 
occlusion during follow-up was more common after CAS (OR 2.00, 95% CI 1.12 to 3.60, P=0.02, I² =44%). 
Conclusions - CAS in patients with symptomatic carotid stenosis is associated with an increased risk of 
stroke or death occurring within 30 days of treatment compared with CEA. The extra risk associated 
with CAS is mostly attributed to an increase in minor, non-disabling strokes occurring in patients older 
than 70 years. Beyond 30 days after treatment, CAS is as effective in preventing recurrent stroke as 
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CEA. However, combining procedural safety and long-term efficacy in preventing recurrent stroke still 
favours CEA over CAS. 
In patients with asymptomatic carotid stenosis, there may be a small increase in the risk of stroke or 
death occurring within 30 days of treatment associated with CAS. However, confidence intervals of 
treatment effects were wide and further data from randomised trials are needed. 
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Introduction 
 
Only randomised trials can answer the question whether CAS is equivalent to CEA in terms of 
treatment safety and long-term prevention of stroke in patients with carotid stenosis. We therefore 
aimed to systematically review all randomised controlled trials comparing CAS with CEA or medical 
care. The present review updates a previous version first published in 1997 and subsequently updated 
in 2004, 2007, and 2012.  
In the 2012 update, sufficient evidence was available to compare treatment risks and short-term 
efficacy between CAS and CEA for symptomatic carotid stenosis. Data on long-term efficacy and for 
treatment of patients with asymptomatic carotid stenosis, however, were sparse. Since the last 
update, four previously identified trials published results of extended follow-up periods and six new 
randomised trials were identified which had completed recruitment and published their results. The 
number of asymptomatic patients available for comparison more than doubled.  
 
Methods 
 
We attempted to identify all unconfounded, truly randomised trials comparing CAS with CEA, and trials 
comparing CAS with medical therapy alone. We included trials in which the exact method of 
randomisation was still uncertain after communication with the authors. We excluded studies of 
carotid revascularisation procedures without control groups and studies without random allocation of 
treatment. We considered trials including patients of any age or either sex with symptomatic or 
asymptomatic carotid stenosis eligible for inclusion in the review. We reviewed trials that allowed any 
acceptable technique for CEA (for example, use of a shunt or not, patching or not, local or general 
anaesthesia) and which allowed any acceptable endovascular technique for treatment of carotid 
stenosis (for example, simple balloon angioplasty, use of a stent or not, any type of cerebral protection 
device). 
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We searched the Cochrane Stroke Group Trials Register (last searched in August 2018), and the 
following bibliographic databases: Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE 
(1950 to August 2018), EMBASE (1980 to August 2018) and Science Citation Index (1945 to August 
2018). We developed the MEDLINE search strategy with the help of the Cochrane Stroke Group Trials 
Search Coordinator and adapted it for the other databases. We also searched the following ongoing 
trials registers (August 2018): Stroke Trials Registry (www.strokecenter.org/trials/); ClinicalTrials.gov 
(http://www.clinicaltrials.gov/); Current Controlled Trials (www.controlled-trials.com). We 
additionally searched reference lists of relevant articles and contacted individual researchers active in 
the field. 
Outcomes 
 
The primary outcome measure for evaluation of treatment safety was the combined outcome of death 
or any stroke occurring between randomisation and 30 days after treatment. For patients who did not 
undergo carotid revascularisation, the corresponding period was defined as the first 30 days after 
randomisation, or according to the definition used in the source trial, in order to allow for intention-
to-treat analysis of all randomised patients. Stroke was defined as an acute deficit of focal neurological 
function with symptoms lasting for longer than 24 hours, resulting from intracranial vascular 
disturbance (ischaemia or haemorrhage). Visual loss, resulting from retinal ischaemia that lasted for 
longer than 24 hours, was included within the category of stroke. Stroke was classified as disabling if 
leading to a loss of functional independence, characterised by a score of three or more on the modified 
Rankin scale58 or the Oxfordshire Handicap Stroke scale59. The primary outcome measure for 
evaluation of combined safety and long-term efficacy was death or any stroke occurring between 
randomisation and 30 days after treatment, or ipsilateral stroke occurring thereafter until the end of 
follow-up. Secondary safety outcomes included the following events occurring between randomisation 
and 30 days after treatment: death or major or disabling stroke, death of any cause, any stroke, 
myocardial infarction, cranial nerve palsy, and access site haematoma. Secondary efficacy outcomes 
included the following events occurring between randomisation and end of follow-up: death or any 
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stroke, the combination of death or any stroke or myocardial infarction, ipsilateral stroke, severe or 
moderate restenosis, and cognitive performance. 
Data collection and analysis 
 
MDM screened the titles and abstracts of records identified from the searches of the electronic 
bibliographic databases and excluded obviously irrelevant studies. We obtained the full text of the 
remaining studies and two review authors (MDM, LHB) independently selected relevant trials based 
on the review inclusion criteria, and assessed trial quality. We resolved disagreements by discussion 
and consultation with the other authors if necessary. 
Two review authors (MDM, PL) extracted trial data. We resolved disagreements by consensus. We had 
access to individual patient data from six trials and used reported outcomes of individual patients from 
two other trials, to perform subgroup analyses. For trials where access to individual patient data was 
available, we extracted short-term outcome events used for comparison of treatment safety according 
to the definition of the peri-procedural period used in this review (i.e. events occurring between 
randomisation and 30 days after treatment). 
We quantified heterogeneity among trial results using the I² statistic and considered a value >50% as 
representing substantial heterogeneity.60 
We analysed outcomes following the intention-to-treat principle, i.e. we compared all patients who 
were randomised and in whom any information on outcome was reported according to their randomly 
assigned treatment, irrespective of whether they received this treatment or not.  
For trials comparing CAS with CEA, we analysed the data from patients with symptomatic and 
asymptomatic carotid stenosis and data from trials enrolling patients considered at increased surgical 
risk separately, whenever possible. For the outcome measures moderate or severe restenosis, cranial 
nerve palsy and access site haematoma, we provided pooled treatment effects including all trials with 
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available data because we did not expect any difference in treatment effects according to symptom 
status or general surgical risk.  
We analysed summary data of all patients randomised and analysed in the included studies with 
Mantel-Haenszel random-effect models. We reported the treatment effects as odds ratios (OR), that 
is, the odds of an unfavourable outcome in patients treated by CAS compared with the corresponding 
odds in patients treated surgically, with a 95% confidence interval (CI). We chose P < 0.05 as the level 
of significance. 
Among the eight trials with available individual patient data, we calculated the OR for the primary 
safety outcome measure separately for patients 70 years or older (which was at or near the mean age 
of the patient populations of most included trials) and younger patients. We also performed subgroup 
analysis by sex. In addition, we investigated for heterogeneity according to the required number of 
carotid endovascular procedures interventionists needed to have performed before joining the trials, 
separating the trials at an arbitrary cut-off of up to 10 procedures, or more. We formally tested 
interactions between treatment effect and subgroup variables using a standard test for heterogeneity 
across subgroup results.60 
Results 
 
To date, we identified 22 randomised controlled trials involving 9,753 patients with available outcome 
data that fulfilled the inclusion criteria (Figure 1).  
Symptomatic carotid stenosis  
 
Eight trials including 5,184 participants compared CAS with CEA in patients with symptomatic carotid 
stenosis at standard surgical risk. The largest among those trials were EVA-3S, SPACE, ICSS, and CREST, 
and are briefly described below. Individual patient-level data from these trials were used for further 
analyses in Project 3 and 4 (sections 6.3. and 6.4.).61 
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The Endarterectomy versus Angioplasty in Patients with Symptomatic Severe Carotid Stenosis (EVA-
3S) was a French multicentre trial, which started in November 2000 and randomised patients with 
≥60% symptomatic carotid stenosis between CAS and CEA. The trial was stopped early by the safety 
committee because of safety and futility concerns in September 2005, after 527 patients had been 
enrolled (CAS: 265 patients, CEA: 262 patients). Two hundred and sixty patients and 257 patients 
received the randomly allocated treatment in the two arms respectively. Results up to six months after 
randomisation were published in 2006,52 and up to four years after randomisation in 2008.62 Results 
of long-term follow-up of a median of 7.1 years were published in 2014.63 
 
The Stent-supported Percutaneous Angioplasty of the Carotid artery versus Endarterectomy trial 
(SPACE) trial randomised 1214 patients with symptomatic carotid stenosis of ≥50% or ≥70% 
(depending on the method of measurement) between CAS (613 patients) or CEA (601 patients) in 
Germany, Austria and Switzerland, from March 2001 until February 2006. Following an interim 
analysis, the trial was stopped by the steering committee for reasons of futility and lack of funding. 
The randomly allocated treatment was initiated in 591 and 567 patients in the two arms respectively. 
Short-term outcomes were published in 2006,51 and results up to two years after randomisation in 
2008.64 
 
The International Carotid Stenting Study (ICSS) randomised 1713 patients with symptomatic carotid 
stenosis of ≥ 50% to CAS (855 patients) or CEA (858 patients) between May 2001 and October 2008 in 
Europe, Australia, New Zealand and Canada. Short-term results up to 120 days after randomisation 
were published in 2010.65 The randomised procedure was initiated in 828 and 821 patients in the two 
arms respectively. Long-term follow-up in this trial ended in 2011 and the results were published in 
2014.66 
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The Carotid Revascularization Endarterectomy versus Stenting Trial (CREST) was a multicentre 
randomised trial conducted in the USA and Canada (CREST 2010). Between December 2000 and July 
2008, 2522 patients with carotid stenosis were randomly assigned to CAS (1271 patients) or CEA (1251 
patients). The trial initially enrolled only patients with symptomatic carotid stenosis, but the eligibility 
criteria were changed in 2005 to include asymptomatic patients in addition to symptomatic patients. 
The final population consisted of 1321 patients with symptomatic and 1181 patients with 
asymptomatic stenosis. Results up to four years after randomisation were published in 2010.50 The 
randomly assigned treatment was initiated in 1152 and 1194 patients in the two arms respectively. 
Results over 10 years of follow-up were published in 2016.67 
 
An additional two small trials included both patients with symptomatic and asymptomatic carotid 
stenosis, but did not report outcomes separately.68, 69 These data were nonetheless included in the 
comparisons for symptomatic carotid stenosis. 
 
In all 10 trials combined, CAS was associated with a higher risk of death or any stroke between 
randomisation and 30 days after treatment than CEA (primary safety outcome; crude risks 7.2% vs. 
4.4%; OR 1.70, 95% CI 1.31 to 2.19, P < 0.0001, I²=5%; Figure 2). CAS was furthermore associated with 
a higher risk of the following outcome measures occurring between randomisation and 30 days after 
treatment than CEA: death or any stroke or myocardial infarction (crude risks 7.8% vs. 5.6%; OR 1.43, 
95% CI 1.14 to 1.80, P = 0.002, I² = 0%), and any stroke (crude risks 6.9% vs. 4.0%; OR 1.78, 95% CI 1.38 
to 2.29, P < 0.00001, I² = 0%). Our subgroup analysis revealed that the OR for the primary safety 
outcome was 1.11 (95% CI 0.74 to 1.64) in patients < 70 years old and 2.23 (95% CI 1.61 to 3.08) in 
patients ≥ 70 years old, resulting in a significant interaction between patient age and treatment 
modality (interaction P = 0.007; Figure 3). In contrast, treatment effects in men (OR 1.82, 95% CI 1.10 
to 3.02, I² = 54%) and women (OR 1.52, 95% CI 0.96 to 2.41, I² = 6%) did not differ significantly 
(interaction P = 0.61; Figure 4). 
24 
 
There was a statistically non-significant trend suggesting a higher rate of death or major or disabling 
stroke with CAS (crude risks 3.2% vs. 2.4%; OR 1.36, 95% CI 0.97 to 1.91, P = 0.08, I² = 0%) than with 
CEA. CAS was associated with lower risks of myocardial infarction (crude risks 0.4% vs. 1.0%; OR 0.47, 
95% CI 0.24 to 0.94, P = 0.03; I² = 0%), cranial nerve palsy (crude risks 0.3% vs. 4.8%; OR 0.09, 95% CI 
0.06 to 0.16, P < 0.00001; I² = 0%), and access site haematomata (crude risks 0.5% vs. 1.8%; OR 0.32, 
95% CI 0.15 to 0.68, P = 0.003; I² = 27%). The combination of death or any stroke up to 30 days after 
treatment or ipsilateral stroke during follow-up (the primary combined safety and efficacy outcome) 
favoured endarterectomy (OR 1.51, 95% CI 1.24 to 1.85, P < 0.0001 ; I² = 0%; Figure 5). However, the 
rate of ipsilateral stroke after the peri-procedural period did not differ between treatments (OR 1.05, 
95% CI 0.75 to 1.47, P = 0.77, I² =0%). 
 
Asymptomatic carotid stenosis 
 
Our literature search identified seven trials including 3,378 participants, which compared CAS with CEA 
in patients with asymptomatic carotid stenosis. The two largest trials, which had enrolled patients with 
asymptomatic carotid stenosis were CREST, which also included patients with symptomatic carotid 
stenosis, and the Randomised Trial of Stent versus Surgery for Asymptomatic Carotid Stenosis (ACT-1). 
The Stent-supported Percutaneous Angioplasty of the Carotid artery versus Endarterectomy trial 2 
(SPACE 2) was stopped early due to slow recruitment.70  
 
ACT-1 was a multicentre randomised controlled trial conducted in the USA. Between April 2005 and 
March 2013, 1,453 patients with asymptomatic carotid stenosis of >70% were randomly assigned in a 
3:1 ratio to CAS (1089 patients) or CEA (364 patients). The initially planned sample size was 1,658 
patients, but the study was stopped prematurely due to slow enrolment. Results over five years of 
follow-up were published in 2016.71  
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In 2009, SPACE 2 began recruiting patients. Initially the trial was planned as a three-armed, randomised 
controlled trial comparing best medical treatment alone (BMT) to endarterectomy plus BMT or 
endovascular therapy plus BMT.72 Due to slow enrolment the study design was amended in 2013 to 
become two parallel randomised trials, one comparing BMT alone to endarterectomy and the second 
comparing BMT to endovascular therapy. This change in study design did not lead to an increase in 
patient recruitment and the trial was stopped early after inclusion of 513 patients over a 5 year period. 
Outcomes within the procedural time period of the recruited patients were reported in 2016.70 
 
In patients with asymptomatic carotid stenosis, we found a statistically non-significant trend towards 
a higher risk of death or any stroke between randomisation and 30 days after treatment (primary 
safety outcome; crude risks 2.6% vs. 1.4%; OR 1.72, 95% CI 1.00 to 2.97, P=0.05; I²=0%; Figure 6) with 
CAS compared with CEA. The risk of death or any stroke up to 30 days after treatment or ipsilateral 
stroke during follow-up did not differ significantly between treatments (OR 1.27, 95% CI 0.87 to 1.84, 
P = 0.22; I² = 0%; Figure 7). 
 
Restenosis 
 
There was statistically no significant difference in risk of severe restenosis (≥70%) or occlusion after 
CAS compared with CEA (OR 1.26, 95% CI 0.79 to 2.00, P=0.33, I² =58%). Moderate or higher restenosis 
(≥50%) or occlusion during follow-up was more common after CAS (OR 2.00, 95% CI 1.12 to 3.60, 
P=0.02, I² =44%). However, we found substantial heterogeneity in both of these comparisons and the 
results must be interpreted with caution. 
 
Discussion and Conclusions 
 
In patients with symptomatic carotid stenosis, CAS and CEA are equally effective in preventing stroke 
in the long-term. However, CAS was associated with a higher risk of stroke or death occurring within 
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30 days of treatment. This excess risk occurred mostly in the form of minor, non-disabling stroke and 
was limited to patients over the age of 70 years. The choice between the two procedures should 
therefore be based on minimising short-term risks. For this reason, symptomatic carotid stenosis 
should not be routinely treated with CAS in patients above the age of 70, provided the patients are fit 
and willing to undergo surgery, and CEA can be performed at standard risk. CAS can be offered as an 
alternative to CEA in patients with symptomatic stenosis who are younger than 70 years at centres 
achieving short-term stroke or death rates in this age group comparable to those with CEA. Factors 
such as patients' preference, cardiovascular risk and vascular anatomy should also be taken into 
consideration in the choice between the two procedures. 
In patients with asymptomatic carotid stenosis, there may be a small increase in the risk of procedure 
related stroke or death occurring within 30 days of treatment associated with CAS. However, the 
quality of the evidence was merely moderate and confidence intervals of treatment effects were wide 
reflecting the need for more data from randomised trials. Concerning the durability of CAS in patients 
with asymptomatic carotid stenosis, only limited data are currently available and the existing evidence 
does not yet allow any firm conclusions. The data urge caution and the results of the ongoing 2nd 
Asymptomatic Carotid Surgery Trial (ACST-2), as well as extended follow-up data from ACT-1 and the 
SPACE-2 are needed. ACST-2 is a multicentre, randomised controlled trial in which patients with 
asymptomatic carotid stenosis considered to require revascularisation are randomised in a 1:1 ratio 
between CAS and CEA. This trial with a planned sample size of 3,600 patients is scheduled to complete 
recruitment by the end of 2019.73 
 
If uncertainty remains whether revascularisation provides benefit over modern medical treatment 
alone, patients should be randomised in CREST-2 (including patients with asymptomatic carotid 
stenosis) or in ECST-2 (including patients with asymptomatic or low-to-intermediate risk symptomatic 
stenosis).  
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Figures 
 
Figure 1 – Study flow chart 
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Figure 2 – Death or any stroke between randomisation and 30 days after treatment in patients with symptomatic carotid stenosis 
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Figure 3 - Death or any stroke between randomisation and 30 days after treatment according to age(<70 years vs. ≥70 years) in patients with symptomatic 
carotid stenosis  
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Figure 4 - Death or any stroke between randomisation and 30 days after treatment according to sex (men vs. women) in patients with symptomatic carotid 
stenosis  
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Figure 5 – Death or any stroke between randomisation and 30 days after treatment or ipsilateral stroke until the end of follow-up in patients with 
symptomatic carotid stenosis 
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Figure 6 - Death or any stroke between randomisation and 30 days after treatment in patients with asymptomatic carotid stenosis  
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Figure 7 – Death or any stroke between randomisation and 30 days after treatment or ipsilateral stroke until the end of follow-up in patients with 
asymptomatic carotid stenosis 
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Abstract 
 
Background and Purpose - Complex vascular anatomy might increase the risk of procedural stroke 
during CAS. Randomised controlled trial evidence that vascular anatomy should inform the choice 
between CAS and CEA has been lacking. 
Methods - We included 184 patients with symptomatic internal carotid artery stenosis who were 
randomly assigned to CAS or CEA in the ICSS (International Carotid Stenting Study) and underwent 
magnetic resonance (n=126) or computed tomographic angiography (n=58) at baseline and brain MRI 
before and after treatment. We investigated the association between aortic arch configuration, angles 
of supra-aortic arteries, degree, length of stenosis, and plaque ulceration with the presence of at least 
one new ischaemic brain lesion on diffusion-weighted magnetic resonance imaging (DWI) after 
treatment.  
Results - In the CAS group, 49 of 97 patients (51%) and 14 of 87 in the CEA group (16%) were had at 
least one new DWI lesion after treatment (OR 6.0; 95% CI 2.9–12.4; P<0.001). In the CAS group, aortic 
arch configuration type 2 or 3 (OR 2.8; 95% CI 1.1–7.1; P=0.027) and the degree of the largest internal 
carotid artery angle (≥60° versus <60°; OR 4.1; 95% CI 1.7–10.1; P=0.002) were both associated with 
new DWI lesions, also after correction for age. No predictors for the occurrence of new DWI lesions 
were identified in the CEA group. The risk for new DWI lesions in CAS increased further over CEA if the 
largest internal carotid artery angle was ≥60° (OR 11.8; 95% CI 4.1–34.1) than if it was <60° (OR 3.4; 
95% CI 1.2–9.8; interaction P=0.035).  
Conclusions - Complex configuration of the aortic arch and internal carotid artery tortuosity increase 
the risk of cerebral ischaemia during CAS, but not during CEA. Vascular anatomy should be taken into 
account when selecting patients for stenting. 
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Introduction 
 
The selection of patients to whom CAS can be offered as an alternative to CEA is controversial. In ICSS, 
CAS carried a higher risk of non-disabling, procedure-related stroke than CEA, but was as effective at 
preventing recurrent stroke in the long term.66 Thus, the choice of the optimal treatment for individual 
patients should be based on minimising procedural risks. In patients with symptomatic carotid 
stenosis, the extra risk of procedural stroke associated with CAS seems to be limited to patients older 
than 70 years,74 the reasons of which remain unclear. Anatomic features of the aortic arch and supra-
aortic arteries may increase procedural risk in CAS,54-56, 75, 76 but also in CEA.77 Randomised trial 
evidence whether vascular anatomy constitutes a risk for procedural stroke independently of age, and 
whether it should inform the choice between CAS and CEA, has been lacking.  
In the magnetic resonance imaging (MRI) substudy of ICSS, three times more patients had new 
ischaemic brain lesions after CAS than after CEA.19 In the present analysis of the ICSS-MRI substudy, 
we investigated the association between vascular anatomies observed on baseline contrast-enhanced 
magnetic resonance angiography (CE-MRA) or computed tomographic angiography (CTA) and the risk 
of subsequent procedure-related cerebral ischaemia. We hypothesized that increased difficulty of 
vascular anatomy would pose patients at greater risk of ischaemia during CAS, but not during CEA. 
Methods 
 
In the ICSS-MRI substudy 231 patients with symptomatic carotid stenosis were examined with brain 
MRI 1-7 days before intervention (pre-treatment scan) and 1-3 days thereafter (post-treatment scan), 
including diffusion-weighted sequences (DWI) to detect ischaemic brain lesions. The primary outcome 
was procedural cerebral ischaemia, defined as the presence of ≥1 new DWI lesion on the post-
treatment scan.19 The study was approved by local ethics committees for non-UK centres and by the 
Northwest Multicentre Research Ethics Committee in the United Kingdom. Patients provided written 
informed consent to undergo MRI when the scans were not part of clinical routine. 
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The following anatomic parameters were defined before assessment and then evaluated on baseline 
CE-MRA or CTA in each patient by a single trained neurologist (MDM) blinded to the findings on brain 
MRI. To test inter-rater reliability, the scans of the first 40 patients were additionally assessed by a 
neuroradiologist (FJA). Degree of stenosis in the ICA (internal carotid artery) considered for treatment 
and in the ipsilateral external carotid artery (ECA) was calculated according to NASCET (North American 
Symptomatic Carotid Endarterectomy Trial) criteria.78, 79 Patients with ICA near occlusion were not 
eligible to participate in ICSS. Length of stenosis was defined as the distance between the proximal and 
the distal shoulder of the plaque, or if not clearly visible, between the proximal and distal point where 
the vessel reached 80% of its original diameter.77 Ulcerated stenosis was defined if fulfilling the criteria 
of an ulcer niche, “seen in profile as a crater penetrating into a stenotic plaque”.80 In addition, the side 
of carotid stenosis (left versus right) was recorded. 
The current configuration of the aortic arch, which represents a combination of variations of the 
original anatomy and acquired changes, was classified using a modification of the original definition81, 
in line with previous studies:57 type 1, if all supra-aortic arteries originated at the level of the outer 
curvature of the aortic arch; type 2, if at least one supra-aortic artery originated between the outer 
and inner curvature; and type 3, if at least one supra-aortic artery originated below the level of the 
inner curvature (Figure 8).  Aortic arch variants such as the left common carotid artery (CCA) originating 
from the brachiocephalic artery were recorded.57, 82 
The angle between the aortic arch and CCA (or brachiocephalic artery) was measured on the plane 
defined by the aortic arch by drawing a tangential line along the outer curvature of the aortic arch 
connecting the origin of the left subclavian artery and the brachiocephalic artery. Then the angle apex 
was positioned at the origin of the CCA or brachiocephalic artery, one angle leg was drawn parallel to 
the tangential line and the second one was placed in the centre of the CCA or brachiocephalic artery 
(Figure 9A). Subsequently, choosing the projection on which the angle was most pronounced, each 
angle along the course of the brachiocephalic artery, between the brachiocephalic artery and the CCA 
(in case of carotid stenosis on the right or stenosis on the left and CCA originating the brachiocephalic 
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artery), and along the CCA and extracranial ICA was recorded if greater than 30° by positioning the 
angle apex at the turning point of the artery, and the angle legs in the centre of the proximal and distal 
segment (Figure 9B). The angle between the CCA and ICA was always recorded. Each angle was 
measured as the change in direction from the caudal to the cranial segment by subtracting the angle 
between the two legs from 180°, as shown by an asterisk (*) in Figure 9. 
 
In addition, we applied a previously published score of anatomic features considered to increase 
procedural risk in CAS.76 The score includes type of aortic arch configuration, arch atheroma,  presence 
of “bovine arch”, i.e. origin of the left CCA from the brachiocephalic artery, CCA disease, pinhole 
stenosis (>90%), ECA stenosis >50%, CCA tortuosity defined as any vessel angulation >90° and ICA 
tortuosity defined as any vessel angulation >60°. 
 
Statistical Analysis 
 
Inter-observer agreement of anatomical parameters between the two raters was tested with intra-
class correlation coefficients (ICC) for continuous variables, with values >0.75 indicating excellent, 
0.40-0.75 fair to good, and <0.40 poor reliability,83 and Cohen’s kappa for categorical variables, with 
values >0.81 indicating excellent, 0.61-0.80 substantial,  and 0.41-0.60 moderate agreement.84 
 
Associations between side, degree and length of stenosis, plaque ulceration, angle between aortic arch 
and brachiocephalic artery or CCA, angle between the brachiocephalic artery and CCA (if applicable), 
largest angle in the CCA, CCA/ICA angle, largest angle in the ICA and type of aortic arch configuration 
and the primary outcome measure were investigated with binary logistic regression in each treatment 
group separately. Continuous variables were dichotomized at the population median. All analyses 
were adjusted for the time interval between treatment and the post treatment MRI, which was longer 
in the CEA group than in the CAS group.19 Analyses were additionally adjusted for age, which is the 
strongest clinical predictor for procedural stroke or death associated with CAS and may itself be 
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associated with complex vascular anatomy. In addition, we tested whether anatomic parameters 
which were significantly associated with the primary outcome measure in one treatment group also 
modified the odds ratio (OR) of the primary outcome measure between CAS and CEA, by testing of 
statistical interaction. SPSS version 22.0, IBM Corp (Chicago, IL, USA) was used.  
 
Results 
 
Baseline CE-MRA (n= 126) or CTA (n=58) was available in 184 of 231 patients (80%) included in the 
ICSS-MRI substudy; 97 were assigned to CAS and 87 to CEA (Figure 10). Clinical, anatomic and 
interventional characteristics were well balanced between groups (Table 1), and broadly comparable 
between patients with and without available baseline vascular imaging, with the exception of a longer 
delay to treatment in the latter group.  
 
Inter-rater agreement was excellent for degree of stenosis (ICC=0.951), length of stenosis (ICC=0.886), 
AO/CCA angle (ICC=0.948), largest CCA angle (ICC=0.968), CCA/ICA angle (ICC=0.887) and largest ICA 
angle (ICC=0.944; p<0.001), and substantial for aortic arch configuration (0.724; 95% CI 0.535 -0.912; 
p<0.001).  
 
Procedural cerebral ischaemia was found in 49 patients in the CAS group (51%) and 14 patients in the 
CEA group (16%; OR 6.0, 95% CI 2.9-12.4, p<0.001). In 6 of the 49 patients in the CAS group and in 2 of 
the 14 patients in the CEA group, the new DWI lesions on the post-treatment scan were associated 
with symptoms of ischaemic hemispheric stroke occurring between initiation of treatment and the 
post-treatment scan. DWI lesions in the remaining patients were silent.19 Among both treatment 
groups combined, stroke symptoms occurred in 5 patients with DWI lesions located in the territory 
supplied by the right carotid artery and in 3 patients with DWI lesions located in the territory supplied 
by the left carotid artery (with or without involvement of other territories).  
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In the CAS group, aortic arch configuration type 2 or 3 as opposed to type 1 (OR 2.8, 95% CI 1.1-7.1, 
p=0.027), as well as the largest angle along the course of the ICA separated at the population median 
(≥60° versus <60°; OR 4.1, 95% CI 1.7-10.1, p=0.002) were associated with cerebral ischaemia (Figure 
11). Both associations remained significant after correction for age (OR 2.9, 95% CI 1.1-7.7, p=0.032; 
and OR 3.4, 95% CI 1.4-8.9, p=0.01; respectively). To account for potential confounding, we additionally 
corrected these associations for the duration of the stenting procedure (OR 2.9, 95% CI 1.1-8.1, 
p=0.038 for ICA angle and OR 2.6, 95% CI 0.9-7.5, p=0.079 for aortic arch configuration, respectively). 
None of the other parameters predicted the occurrence of cerebral ischaemia (Figure 11). In addition, 
patients with a higher score of anatomic difficulty76 were also at increased risk for cerebral ischaemia 
(OR 3.2, 95% CI 1.3-7.9, p=0.014, values separated at the population median 4.3), but not after 
correction for age (OR 2.2, 95% CI 0.8-5.7, p=0.123). 
 
In the surgery group, none of the assessed parameters for vascular anatomy or stenosis characteristics 
(or the expert score for anatomic suitability) were significantly associated with procedural cerebral 
ischaemia. However, we observed a non-significant trend that patients with aortic arch configuration 
type 2 or 3 had a higher risk of cerebral ischaemia (OR 3.5, 95% CI 0.7-17.1; Figure 11). 
 
We performed a sensitivity analysis excluding patients without available arch angiography from all 
analyses: Among 89 remaining patients in the CAS group, the association between cerebral ischaemia 
and largest ICA angle ≥60° remained statistically significant (OR 3.2, 95% CI 1.2-8.5, p=0.023). In the 
remaining 76 patients in the CEA group, we again found no significant associations. 
 
The interaction between the largest ICA angle and the effect of treatment (CAS versus CEA) on cerebral 
ischaemia was statistically significant: the extra risk of DWI lesions in CAS increased further over CEA 
if the largest ICA angle was ≥60° (OR 11.8, 95% CI 4.1-34.1) than if it was <60° (OR 3.4, 95% CI 1.2-9.8, 
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interaction p=0.035). The interactions between treatment effect and aortic arch configuration or 
anatomic suitability score were not significant (Figure 12).  
 
Discussion 
 
In this substudy of a randomised trial comparing CAS versus CEA for symptomatic carotid stenosis, 
difficult configuration of the aortic arch as well as the largest angle along the course of the ICA were 
found to increase the risk of procedural cerebral ischaemia in patients treated with stenting, but not 
in patients undergoing endarterectomy. ICA angulation differentially increased the extra risk of 
cerebral ischaemia associated with CAS versus CEA. 
 
In most previous studies investigating procedural stroke risk in CAS, vascular anatomy was assessed on 
digital subtraction angiography (DSA) performed as part of the procedure. To date, no study has 
compared the impact of vascular anatomy on procedural risks between CAS and CEA. We assessed 
baseline non-invasive carotid imaging (CE-MRA and CTA) obtained at the time of random assignment 
to CAS or CEA, before treatment was initiated. These tests are commonly available and used in routine 
diagnostic work-up for carotid disease. Hence, our findings seem more relevant to inform the choice 
between CAS and CEA among patients with symptomatic carotid stenosis in routine practice than the 
results of studies based on pre-procedural DSA.  
 
A complex configuration of the aortic arch and the supra-aortic arteries increases the technical 
difficulty of the stent procedure. Repeated attempts to advance the catheter and guide wire may cause 
endothelial micro-trauma or dislodge atherosclerotic plaque and ultimately cause cerebral emboli. The 
protocol of ICSS did not contain detailed precautions against these complications, such as advice on 
catheter and guidewire handling, limiting guidewire manoeuver time between flushing, syringe 
aspiration and cleansing, concentration of heparin in saline flush, use of constant infusion via infusion 
ports to stopcocks, etc. We are therefore unable to verify that all possible precautions against 
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thromboembolism were taken. This limitation must be borne in mind when interpreting the results of 
our study. 
 
Despite this important limitation, key findings of our study were supported by previous research. 
Faggioli et al. reported a statistically significant association between aortic arch configuration and 
variants such as origin of the left CCA from the brachiocephalic artery (termed “bovine arch”) and the 
incidence of neurological complications in patients undergoing CAS.82 In our study, we were able to 
confirm an increased incidence of cerebral ischaemia in patients with type 2 or 3 aortic arch 
configuration. The aortic arch variant mentioned above was present in 11% of our study population, 
which is within the frequency range reported in the literature, and showed no association with the 
occurrence of new lesions on MRI after treatment, possibly because of a lack of power. 
 
With regard to tortuosity of the supra-aortic arteries, a higher risk of stroke or death within 30 days of 
CAS has been reported in patients with ICA/CCA angulation ≥60° on pre-procedural DSA.56 Other 
authors described a significant association between tortuosity of the CCA and proximal ICA and the 
occurrence of complications in CAS, but found no increase in adverse events in patients with tortuous 
ICA distal to the stenosis.55 We were able to confirm that greater tortuosity along the course of the ICA 
increases the incidence of cerebral ischaemia in CAS.  
 
A scoring system derived from expert opinion has been developed to grade the difficulty of vascular 
anatomy (and hence to judge the suitability of the patient) for CAS.76 Our results suggest that this 
system might indeed be able to predict the occurrence of ischaemic brain lesions in patients with 
symptomatic carotid stenosis undergoing CAS, although perhaps not independently of age.  
 
We found no significant association between supra-aortic vascular anatomy or stenosis characteristics 
and procedural cerebral ischaemia in the surgery group. Problems with CAS related to navigating 
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difficult vascular anatomy do not apply to endarterectomy where the atherosclerotic lesion can be 
directly accessed. However, there was a strong non-significant trend that patients with aortic arch 
configuration type 2 or 3 had a higher risk of cerebral ischaemia, possibly because these configurations 
are associated with increased atherosclerotic burden or represent markers of vascular risk in general.   
 
By including two broadly comparable treatment groups in this observational substudy of a randomised 
trial, we were able to investigate whether a given anatomic risk predictor would modify the relative 
risk of cerebral ischaemia between CAS and CEA, by formal testing for statistical interaction. The extra 
risk of DWI lesions associated with CAS increased further over CEA if the largest measured ICA angle 
was ≥60° (the population median) than if it was <60°. ICA tortuosity therefore seems to be a feature 
which should specifically be taken into account when deciding between CAS and CEA.  
 
Characteristics of the carotid plaque (degree and length of ipsilateral stenosis and plaque ulceration) 
studied on CE-MRA and CTA did not predict the occurrence of new DWI lesions after CAS, in line with 
a previous DSA-based substudy of ICSS.85 In contrast, several studies showed that the presence of an 
ulcerated plaque on pre-procedural DSA increases the risk for the occurrence of DWI lesions after 
stenting.86-88 In addition, lesion length has been found to constitute a risk factor for adverse events in 
CAS,77, 86-88 but also in CEA.77 CE-MRA and CTA are inferior to DSA in accurately depicting plaque 
ulceration and lesion length which might explain the discrepant findings between these studies and 
ours. 
 
Older age has consistently been shown a risk factor for procedural stroke in CAS, but not in CEA.74 It 
has been speculated whether the association might be mediated by vascular anatomy. Elongation of 
the aortic arch and supra-aortic arteries was found to be more prevalent in elderly patients,54, 57 
possibly leading to more difficulties during the CAS procedure. Notably in our analysis, the associations 
between ICA angulation and aortic arch configuration with cerebral ischaemia in the stenting group 
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remained significant after correction for age. Hence, vascular anatomy should be taken into account 
when selecting the appropriate treatment option for an individual patient, independent of the 
patient’s age.  
 
This analysis has further limitations. The fact that the ICSS protocol excluded patients with a stenosis 
that was thought to be unsuitable for stenting because of proximal tortuous anatomy is likely to have 
limited the number of patients with very unfavourable anatomy. The full impact of vascular anatomy 
on CAS risk may therefore have been underestimated in this study. Secondly, although allocation of 
treatment was randomised, only seven out of 50 study sites participated in the ICSS-MRI substudy, and 
not all patients enrolled in ICSS at these sites completed the substudy for various reasons, as previously 
reported.19 Analysing a subset of a clinical trial implies many of potential risks: the population of the 
substudy may differ from the original trial population and treatment groups in the substudy may differ 
in characteristics not measured in the trial because of selection bias. Thirdly, the classification of aortic 
arch configuration used in this study did not capture the full spectrum of anatomic variation seen in 
practice; in particular, we did not assess varying degrees of separation between origins of left CCA and 
brachiocephalic arteries. Fourth, the limited power of our study has several implications: the observed 
associations in the CAS group must be interpreted with caution. The lack of adjustment for other 
clinical predictors of CAS risk because of limited power, such as previous stroke and atrial fibrillation,88, 
89 represents an important drawback; and a true impact of vascular anatomy on CEA risk may have 
been missed. Nonetheless, we think that the observed associations between vascular anatomy and 
cerebral ischaemia in the stenting group are valid, because they confirm the findings of previous, non-
randomised studies. Finally, a key limitation for the generalizability of our findings to modern practice 
is that technical advances in access routes (cervical versus femoral), stent design (e.g. multi-layered 
stents) and cerebral protection devices (e.g. flow-reversal) have likely lowered the risk of 
thromboembolic complications in CAS since the time of recruitment in ICSS. Patients with complex 
vascular anatomy may derive the greatest benefit from these advances. Protection devices were only 
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used in a minority of patients and they were mostly of the distal filter type. A previous analysis of the 
ICSS-MRI data showed that - contrary to their intended purpose and the results of previous MRI-based 
studies20 - the use of distal protection devices was associated with an increased risk of DWI lesions.19  
 
Conclusions 
 
In this MRI substudy of a randomised trial, we have shown that ICA angulation and difficult 
configuration of the aortic arch both represent possible risk factors of cerebral ischaemia during 
stenting for symptomatic carotid stenosis, independent of patient age. No anatomic parameters 
significantly increasing the risk of endarterectomy were identified. ICA angulation was the sole 
parameter differentially increasing the risk of cerebral ischaemia with stenting versus endarterectomy. 
The risk of cerebral ischaemia might be lower and the observed associations with aortic arch 
configuration and carotid anatomy weaker, or no longer present at all, if technical precautions against 
thromboembolism were maximized, including the use of modern cerebral protection systems.  
Nonetheless, vascular anatomy should be taken into account before selecting patients for stenting, 
irrespective of their age.  
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Figures 
 
Figure 8 - Classification of aortic arch configuration according to the origin of the supra-aortic 
arteries on contrast-enhanced magnetic resonance angiography.  
 
The two horizontal lines mark the outer and inner curvature of the aortic arch. The figure illustrates a 
type 2 aortic arch configuration. 
 
  
47 
 
Figure 9 – Measurement of vessel angles on contrast-enhanced magnetic resonance angiography.   
 
9A - Assessment of the angle between aortic arch and left CCA: first, a parallel line to the upper 
curvature of the aortic arch is drawn by connecting the origin of the brachiocephalic artery and the left 
subclavian artery. Then, one angle leg is positioned parallel to the tangent and the other in the centre 
of the left CCA respecting its distal course. (Of note, the left vertebral artery in this patient, instead of 
originating from the subclavian artery, has a combined origin with the latter). 9B - Assessment of angles 
in the course of the ICA:  the angle apex is positioned at the turning point of the vessel and the legs at 
the centre of the ICA respecting its distal and proximal course. Angles were measured as the change in 
direction from the caudal to the cranial segment by subtracting the angle between the two legs from 
180°, as shown by an asterisk (*) in figure 9.  
  
* 
* 
9B 
ICA angle 2: 
51° 
ICA angle 1: 
90° 
AO/CCA angle: 
 
9A 
* 
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Figure 10 - Study flow diagram.  
 
Diagram depicting the two treatment arms of the study, including events that precluded patients 
from analysis. Scans are magnetic resonance imaging (MRI). BMT = best medical treatment; CAS = 
carotid artery stenting; CEA = carotid endarterectomy; DWI = diffusion weighted imaging; MI = 
myocardial infarction  
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Figure 11 – Risk factor analysis.  
 
Impact of vascular anatomy on the risk of new DWI lesions after carotid artery stenting (CAS) and 
carotid endarterectomy (CEA). Data are numbers of patients with new DWI lesions on post-treatment 
MRI scans (n) and total numbers of patients (N) per group. Circles and horizontal lines are odds ratios 
(OR) and 95% confidence intervals (CI) for presence of new DWI lesions in patients with versus 
without each risk factor, adjusted for interval between treatment and post-treatment scan and age. 
Continuous variables (degree and length of stenosis, angles and expert score for anatomic suitability) 
were separated at the median values of the study population. Missing data: In the CAS group the 
aortic arch was not visible in 8 patients; in the CEA group the aortic arch was not visible in 11 
patients. CCA = common carotid artery; ICA = internal carotid artery. 
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Figure 12 – Subgroup analysis.  
 
Data are numbers of patients with new DWI lesions on post-treatment scans (n) and total numbers of 
patients (N) per treatment group. Circles and horizontal lines are odds ratios (OR) and 95% confidence 
intervals (CI) for presence of new DWI lesions in patients treated with carotid artery stenting (CAS) 
versus carotid endarterectomy (CEA), adjusted for interval between treatment and post-treatment 
scan. Continuous variables were separated at the median values of the study population. Interaction 
p-values are shown. Missing data: In the CAS group the aortic arch was not visible in 8 patients; in the 
CEA group the aortic arch was not visible in 11 patients. ICA = internal carotid artery.  
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Tables 
 
Table 1- Patient and intervention characteristics 
 
CAS 
(n=97) 
CEA 
(n=87) 
Age (years) median (IQR)  70.45 (14.4) 71.65 (13.8) 
Male n (%) 65 (67%) 65 (74.7%) 
Vascular risk factors n (%) 
    Hypertension 67 (69.1%) 63 (72.4%) 
    Diabetes 18 (18.6%) 19 (21.8%) 
    Hyperlipidaemia 56 (57.7%) 55 (63.2%) 
    Smoking 73 (75.3%) 65 (74.7%) 
    Peripheral artery disease 17 (17.5%) 12 (13.8%) 
    Coronary heart disease 24 (24.7%) 20 (23.0%) 
Qualifying event type n (%) 
    Retinal or TIA 56 (57.7%) 52 (59.7%) 
    Hemispheric stroke 41 (42.3%) 35 (40.2%) 
Contralateral severe stenosis or occlusion n (%) 20 (20.6%) 16 (18.4%) 
Delay to treatment (days) median (IQR) 30 (63) 40 (52) 
Anatomical risk factors 
    Left sided stenosis n (%) 47 (48.5%) 38 (43.7%) 
    Type of aortic arch configuration   
Aortic arch type 1 n (%) 37 (38.1%) 28 (32.2%) 
Aortic arch type 2 or 3 n (%) 52 (53.6%) 48 (55.2%) 
Left CCA originating from the brachiocephalic 
artery n (%) 
11 (11.3%) 10 (11.5%) 
Aortic arch not visible n (%) 8 (8.2%) 11 (12.6%) 
    Largest CCA angle median (IQR) 48 (45) 52.5 (35) 
    Angle CCA-ICA median (IQR) 24 (22) 27 (21) 
    Largest ICA angle median (IQR) 57 (32) 66 (47) 
    Degree of stenosis median (IQR) 72.13 (20) 75.0 (23) 
    Length of stenosis median (IQR) 6.3 (6) 6.0 (4) 
    Plaque ulceration n (%) 16 (16.5%) 19 (21.8%) 
Expert score of anatomic suitability median (IQR) 4.0 (2.2) 4.3 (2.2) 
Cerebral protection device  
    Cerebral protection device used n (%) 31 (36%) - 
    No cerebral protection device used n (%) 55 (64%) - 
Stent design  
    Open cell n (%) 53 (61.6%) - 
    Closed cell n (%) 33 (38.4%) - 
Type of anaesthesia  
    General anaesthesia n (%) - 71 (81.6%) 
    Local anaesthesia n (%) - 10 (11.5%) 
Patch 
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    Patch used n (%) - 49 (56.3%) 
    No patch used n (%) - 19 (21.8%) 
Shunt  
   Shunt used n (%) - 11 (12.6%) 
   No Shunt used n (%) - 76 (87.4%) 
 
Baseline data of patients in the stenting and endarterectomy group as well as details of stenting and 
endarterectomy procedure. Percentages exclude missing data; missing data were: Carotid artery 
stenting (CAS) group: n=11 patients no interventional details known; carotid endarterectomy (CEA) 
group: n= 6 patients no information on type of anaesthesia available, n=19 patients no information on 
patch use available. IQR = interquartile range; TIA = transient ischaemic attack; CCA = common carotid 
artery; ICA = internal carotid artery.  
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Abstract 
 
Background and Purpose - Stenting for symptomatic carotid stenosis (CAS) carries a higher risk of 
procedural stroke or death than endarterectomy (CEA). It is unclear whether this extra risk is present 
both on the day of procedure and within 1-30 days thereafter and whether clinical risk factors differ 
between these periods.  
Methods - We analysed the risk of stroke or death occurring on the day of procedure (immediate 
procedural events) and within 1-30 days thereafter (delayed procedural events) in 4597 individual 
patients with symptomatic carotid stenosis who underwent CAS (n=2326) or CEA (n=2271) in four 
randomised trials. 
Results - Compared with CEA, patients treated with CAS were at greater risk for immediate procedural 
events (110 versus 42, 4.7% versus 1.9%; OR 2.6, 95% CI 1.8-3.8), but not for delayed procedural events 
(59 versus 46, 2.5% versus 2.0%, OR 1.3, 0.9-1.9; interaction p=0.005). In patients treated with CAS, 
age increased the risk for both immediate and delayed events, while qualifying event severity only 
increased the risk of delayed events. In patients treated with CEA, we found no risk factors for 
immediate events, while a higher level of disability at baseline and known history of hypertension were 
associated with delayed procedural events.  
Conclusions - The increased procedural stroke or death risk associated with CAS compared with CEA 
was caused by an excess of events occurring on the day of procedure. This finding demonstrates the 
need to enhance the procedural safety of CAS by technical improvements of the procedure and 
increased operator skill. Higher age increased the risk for both immediate and delayed procedural 
events in CAS, mechanisms of which remain to be elucidated. 
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Introduction 
 
In patients with recently symptomatic carotid stenosis, CAS is associated with a higher risk of stroke or 
death in the peri-procedural period than CEA.61  Within this 30-day period, it has been unclear whether 
the extra risk associated with CAS is present both on the day of procedure and within 30 days 
thereafter.  
 
The Carotid Stenosis Trialists’ Collaboration (CSTC) pooled data of individual patients with symptomatic 
carotid stenosis enrolled in the Endarterectomy Versus Angioplasty in patients with Symptomatic 
Severe Carotid Stenosis trial (EVA-3S), the Stent-Protected Angioplasty versus Carotid Endarterectomy 
trial (SPACE), the International Carotid Stenting Study (ICSS) and the Carotid Revascularization 
Endarterectomy versus Stenting Trial (CREST). All trials have completed their long-term follow-up and 
the results have been published.63, 64, 66, 67  
 
In the present analysis, we compared the risk of stroke or death occurring on the day of procedure and 
within 1-30 days following both treatments. In addition, we investigated if clinical risk factors for stroke 
or death differed between these periods.  
 
Methods 
 
The data that support the findings of this study are available from the corresponding author upon 
reasonable request. This meta-analysis includes individual patient data from EVA-3S (NCT 00190398), 
SPACE (ISRCTN 57874028), CREST (NCT00004732) and ICSS (ISRCTN 25337470). Patients were 
recruited from 2000-2005 in EVA-3S, from 2001-2006 in SPACE, from 2001-2008 in ICSS, and from 
2000-2008 in CREST. Ethics approval for the contributing trials was obtained at the competent 
institutional review boards and all patients provided written informed consent. The pooled analysis of 
individual patient data was agreed upon at the design stage of these trials.90 All four trials were 
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randomised clinical trials with blinded outcome adjudication. Detailed inclusion and exclusion criteria 
of all trials have been reported previously.49, 91-93 In summary, all trials included patients with 
symptomatic moderate to severe carotid stenosis (≥50% reduction of lumen diameter measured 
according to the method used in the NASCET), who were equally suitable for either procedure. CREST 
additionally included patients with asymptomatic carotid stenosis, but only data from symptomatic 
patients were included in the present analysis. Patients were randomly allocated in equal proportions 
to CAS or CEA.  
 
In EVA-3S, SPACE and ICSS all stents had to be CE (Communauté Européenne) marked. In CREST, the 
protocol specified the use of the RX Acculink stent. In EVA-3S, the use of distal filter protection devices 
became mandatory early in the trial, after the risk of stroke within the procedural period was found to 
be unacceptably high in patients treated with unprotected CAS. In CREST, the use of the RX Accunet 
embolic protection device was recommended whenever feasible. In ICSS and SPACE, the use of 
protection devices remained optional throughout the trials. Surgeons could perform standard or 
eversion endarterectomy under local or general anaesthesia, with or without the use of shunts or 
patches. CAS or CEA were deemed initiated if the patient had been given general or local anaesthetic 
in preparation for the intervention. 
 
The primary outcome event for this analysis was stroke or death occurring either on the day of 
treatment (immediate procedural event) or within 1-30 days thereafter (delayed procedural event). 
Stroke was defined as an acute deficit of focal neurological function which led to symptoms lasting 
longer than 24 hours, resulting from intracranial vascular disturbance (ischaemia or haemorrhage). For 
the present analysis, only the first event was considered, because we assumed that second events (e.g. 
death or another stroke occurring after a first stroke) would rarely be independent of the first event. 
In addition, second events of the same type occurring in the peri-procedural may not have been 
reported separately in the source trials. 
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Statistical analysis 
 
The primary analysis population included all patients in whom the randomly allocated treatment was 
initiated (per-protocol analysis).61 Patients crossing over to the other treatment, those who did not 
receive either treatment, and those who died before treatment were excluded. A per-protocol analysis 
rather than intention-to-treat analysis was chosen because the main difference between the two 
analysis populations consisted of patients who did not receive either treatment (Figure 13). In addition, 
the primary aim of our research question was to investigate whether the risk of stroke or death differed 
between CAS and CEA in two distinct time periods (day of treatment and 1-30 days after treatment).  
 
Data were analysed with generalized linear mixed-effects models (GLMM) with binomial error and logit 
link function, with a random intercept for each source trial. The CAS versus CEA treatment effect was 
expressed as an odds ratio (OR) with 95% confidence interval (CI), both for immediate procedural 
events and for delayed procedural events, with CEA as the reference treatment. To investigate 
whether the CAS versus CEA treatment effect differed between the immediate and delayed procedural 
period, we reshaped the analysis set to include two observations (rows) per patient, one for immediate 
procedural events and one for delayed procedural events, and included a random intercept for each 
source trial and patient. We chose this approach to be able to investigate whether the odds ratio for 
the primary outcome differed between the immediate and the delayed procedural period by formal 
testing of statistical interaction. We did this by including treatment (CAS versus CEA), time of event 
(immediate versus delayed) and an interaction term between treatment and time in the model. We 
performed a sensitivity analysis excluding patients who had the primary outcome event in the 
immediate procedural period from the population at risk in the delayed procedural period. 
We investigated if the following baseline patient characteristics were associated with stroke or death 
in the immediate (day 0), the delayed (day 1-30) and the full procedural period (day 0-30) by a forward 
variable selection approach based on the Akaike information criterion (AIC), in each treatment group 
separately: patient age and sex, systolic blood pressure at baseline, previous diagnosis of hypertension, 
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diabetes mellitus, hyperlipidaemia and coronary heart disease, any history of smoking (current or 
past), modified Rankin Scale at baseline, degree of ipsilateral stenosis measured according to NASCET 
criteria78 dichotomized into moderate (50-69%) or severe (70-99%), presence of contralateral stenosis 
(≥70%) according to NASCET criteria78 or occlusion, and severity of the qualifying event (analysed by 
trend: hemispheric ischaemic stroke > TIA > ocular ischaemia [including amaurosis fugax or retinal 
infarction]). Qualifying event severity was analysed by trend because patients with previous ocular 
events have a lower risk of future ischaemic stroke compared to patients who had a TIA, and patients 
with a TIA have a lower risk than patients who had a hemispheric stroke.36 
 
To investigate if associations between patient characteristics and procedural events differed between 
the immediate and the delayed procedural period, we again used the data structure with two 
observations per patient (using the subset with CAS or CEA) and included baseline patient 
characteristics which were associated with immediate or delayed procedural events and their 
interactions with time.  
 
In addition, we fitted a GLMM for the immediate, the delayed and the full procedural period each, 
adjusted for any variables identified as significant predictors of the primary outcome event in any of 
these periods by the forward selection approach described above. We used these models to display 
the risk factor associations for the different periods in a forest plot.  
 
A p-value of <0.10 for interaction terms was considered statistically significant. For all other statistical 
analyses, a p-value of <0.05 was considered to indicate statistical significance. All statistical analyses 
were performed as complete case analyses (no imputation of missing values), using the statistical 
software environment R (Version 3.4.1; R Foundation for Statistical Computing, Vienna, Austria). 
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Results 
 
In total, 5956 patients were enrolled in the four contributing trials. The pooled per-protocol analysis 
set included 4,597 patients, 2,271 of whom received CEA and 2,326 CAS. Reasons for exclusion of 
patients from the per-protocol analysis are provided in Figure 13. Baseline characteristics were well 
balanced between the stenting and the endarterectomy group (Table 2). In ICSS, SPACE and EVA-3S 
closed-cell stents were used in 61.8%, while in CREST the use of the open-cell RX Acculink stent device  
was mandatory. In CREST 96.1% of patients were treated with the RX Accunet embolic protection 
device, while in ICSS, SPACE and EVA-3S 61% of patients were treated with various embolic protection 
devices.94 
 
A total of 257 patients had a stroke or died during the full 30-day procedural period, 169 in the CAS 
group (7.3% risk) and 88 in the CEA group (3.9% risk; OR 1.94, 95% CI 1.50-2.53). Compared with CEA, 
patients treated with CAS more often had a stroke or died on the day of procedure (110 versus 42 
patients, 4.7% versus 1.9% risk; OR 2.64, 95% CI 1.84-3.78), but not between 1 and 30 days thereafter 
(59 versus 46 patients, 2.5% versus 2.0% risk, OR 1.26, 0.84-1.87; Figure 14). The treatment effect ORs 
differed significantly between the time periods (interaction p=0.006). We performed a post-hoc 
sensitivity analysis excluding all patients who experienced the outcome measure on the day of 
procedure (n=152) from the population at risk for an event between day 1-30. This yielded very similar 
results compared to our original model and we again found no significant difference in the occurrence 
of the outcome measure between CAS and CEA between day 1-30 (OR 1.30, 95% CI 0.87-1.91). Only 
two patients who had a stroke on day 0, had another stroke between day 1-30. 
Details of outcome events are provided in Table 3. In both treatment groups, the large majority of 
strokes, both occurring on the day of procedure and between day 1 and 30 after procedure, were 
located in the territory supplied by the treated carotid artery. In both treatment groups combined, 2 
of 151 strokes (1%) occurring on the day of procedure and 15 of 95 strokes (16%) occurring between 
day 1 and 30 after the procedure were of haemorrhagic type. 
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In the stenting group, the forward selection model identified age and smoking as independent 
predictors of immediate procedural events:  age was positively (OR 1.54 per decade, 95% CI 1.21-1.95) 
and smoking was negatively (OR 0.61, 95% CI 0.40-0.91) associated with stroke or death occurring on 
the day of treatment. For the delayed procedural period (day 1-30 after treatment) age (OR 1.63 per 
decade, 95% CI 1.21-2.21) and qualifying event (QE) severity (stroke > TIA > ocular ischaemia, analyzed 
by trend; OR 1.54, 95% CI 1.03-2.31) were found to be significant predictors for stroke or death. There 
were no significant differences in the strength of the associations between these risk factors and 
events between the immediate and delayed procedural period with the exception of smoking 
(interaction p=0.061; Figure 15). For the entire procedural period both age (OR 1.63 per decade, 95% 
CI 1.37-1.95) and QE severity (analysed by trend; OR 1.31, 95% CI 1.04-1.64) remained significant 
predictors for stroke or death occurring between day 0-30 after treatment.  
 
In the endarterectomy group, we found no significant predictors for immediate stroke or death. 
However, a higher level of disability at baseline, assessed with the modified Rankin Scale, was a 
significant predictor for delayed stroke or death (OR 1.42, 95% CI 1.10-1.84). The association between 
this risk factor and procedural stroke or death did not differ significantly between the immediate and 
delayed procedural period (Figure 16). Higher level of disability at baseline and history of hypertension 
were found to be significant predictors for stroke or death in the full procedural period (OR 1.24, 95% 
CI 1.01-1.51, and OR 1.84, 95% CI 1.04-3.33, respectively).  
 
Discussion 
 
In this pooled analysis of individual patient data from four randomised clinical trials, we found that the 
excess occurrence of procedural stroke or death associated with CAS compared with CEA was limited 
to the day of treatment. For the remainder of the procedural period, there was no difference in the 
risk of stroke or death between the two treatments. Age was a risk factor for stroke or death in the 
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CAS group, notably both in the immediate (day of procedure) and the delayed procedural period (day 
1-30). 
 
Procedure-related stroke or death in carotid revascularization is commonly defined as all events 
occurring within 30 days after the procedure. However, from experience, most such events occur on 
the day of treatment. In our analysis, we were able to confirm this assumption. We found that about 
two thirds (110 out of 169) of all procedural stroke or death outcomes in patients receiving CAS and 
about half (42 out of 88) of the events in patients treated with CEA occurred on the day of procedure. 
On the day of procedure, the risk of procedural stroke or death was significantly higher in CAS than in 
CEA, but between 1 and 30 days thereafter the risk was similar in both treatment groups. 
 
Stroke or death events occurring on the day of procedure might differ in pathogenesis and associated 
risk factors from events occurring later in the 30-day period. However, as far as clinical risk factors are 
concerned, we found no significant differences in the observed associations between the immediate 
and delayed procedural period. Most importantly, increasing age among patients treated with CAS was 
significantly associated with procedural stroke or death in both the immediate (day of procedure) and 
delayed procedural (day 1-30) period. It has been hypothesized that higher age is associated with 
vessel elongation and therefore more pronounced angulation of the vasculature, and that the 
resulting, more complex anatomy of the supra-aortic arteries could lead to increased technical 
difficulty of the procedure and hence to the higher risk associated with CAS in older patients.54, 57 Our 
finding that age is associated with an increase in both immediate and delayed procedural events argues 
against vascular anatomy as the sole mediating factor. Older patients might have more unstable 
atheromatous lesions than younger patients, which may cause thromboembolic strokes not only on 
the day of procedure, but also during the following days.95, 96 However, the mechanisms mediating the 
association between age and procedural risk of CAS remains poorly understood; our finding that older 
patients are also at risk for delayed procedural events adds to the complexity of this matter.  
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Interestingly, we found that history of smoking decreased the risk of stroke or death on the day of 
procedure in the CAS group. A similar association with stroke or death in the full procedural period 
was already described in ICSS.40 One possible explanation for this rather surprising relationship might 
have been that smokers were younger than non-smokers and hence at lower risk. Indeed, the mean 
age of smokers in our study population was 67.5 years, while the mean age of non-smokers was 72.5 
years.  However, the effect of smoking was adjusted for age in our analysis indicating that the inverse 
association with stroke or death is not confounded by age. Nevertheless, we cannot rule out that this 
unexpected finding was due to residual confounding by patient characteristics not measured in the 
trials.  
 
The fact that the excess of procedural stroke or death occurring in the stenting group is limited to the 
day of procedure suggests that these events might potentially be avoided by improving operator skill 
or technical aspects of the procedure itself. Whether the use of intraluminal protection devices 
reduces the risk of embolic stroke is a matter of ongoing controversy. In EVA-3S the use of distal filter 
protection devices became mandatory early in the trial, after the risk of stroke within the procedural 
period was found to be about three times higher in patients treated with unprotected CAS. In CREST 
the use of cerebral protection devices was recommended whenever feasible. In ICSS and SPACE the 
use of protection devices remained optional throughout the trials. The ICSS-MRI substudy showed that 
the use of distal filter devices, which was the type of protection device predominately used in all four 
contributing trials, was associated with an increased risk of new ischaemic brain lesions after the 
procedure.19 Two small randomised studies comparing stenting with embolic filter protection to 
unprotected stenting confirmed these results.46, 47 In light of these findings, considerable uncertainty 
remains, whether distal filter devices truly increase the safety of CAS.  
 
Irrespective of this question, one must acknowledge the fact that the trials contributing to the present 
analysis largely enrolled their patients in the 2000s and that considerable technical advance of CAS has 
63 
 
occurred since. For example, alternative methods of cerebral protection such as systems exerting a 
reversal of blood flow before the lesion is crossed with the catheter have been introduced and appear 
to lower the risk of thromboembolism.97 However, not all patients tolerate flow reversal in the carotid 
artery and to date insufficient data exist to justify a general recommendation for the use of such 
devices, although the available data seem promising.98, 99 The ARMOUR (Proximal Protection with the 
Mo.MA Device During Carotid Stenting) study investigated the safety and effectiveness of proximal 
embolic protection with the Mo.MA device and showed a very low 30-day stroke rate of 0.9%.99 
Another possible source of thromboembolism to the brain during stenting is the aortic arch and the 
access vasculature. To avoid the necessity of navigating the aortic arch with potentially difficult 
anatomy, alternative access routes such as direct carotid access have been proposed.100 The ROADSTER 
(Reverse Flow Used During Carotid Artery Stenting Procedure) study investigating CAS with direct 
transcarotid access and proximal embolic protection showed a very low 30-day stroke rate of 1.4%.101 
Although the ARMOUR and the ROADSTER studies enrolled patients with both symptomatic and 
asymptomatic carotid stenosis, which renders a direct comparison with our results difficult, these low 
stroke rates are remarkable.  
 
In the endarterectomy group, the only clinical risk factors found to influence the risk of stroke or death 
were a higher level of disability at baseline and known history of hypertension. Hypertension increased 
the risk for stroke or death over the entire procedural period of 30 days, a finding which is consistent 
with previous reports.36 
This analysis has important limitations. First, we did not collect information as to the mechanism of 
stroke across all four contributing trials (e.g. embolic, haemodynamic, stent thrombosis). Second, with 
regard to events occurring on the day of treatment, we do not know if the events occurred during or 
after the procedure, as the exact timing of stroke or death was not recorded. Third, all participating 
trials recruited patients between 2000 and 2008. Since that time, there has been substantial progress 
in the development of new stent designs, the introduction of cerebral protection devices and new 
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access routes, all of which may help reduce the risk of immediate procedural complications. Thus, the 
peri-procedural stroke rate among patients with symptomatic carotid stenosis using current 
generation CAS technologies and cerebral protection devices may be lower than demonstrated in 
these 4 trials. Fourth, in order to be able to investigate whether the CAS versus CEA treatment effect 
differed between the immediate and delayed procedural period by formal tests of statistical 
interaction, we included all patients in the population at risk for an event between day 1-30, even 
those who experienced an event on the day of procedure (n=152). However, in a post-hoc analysis 
excluding these patients from the population at risk for an event between day 1-30, the results 
remained essentially unchanged.  
 
The fact that the increased risk of stroke or death in the stenting group is limited to the day of 
procedure demonstrates the need to improve the procedural safety of carotid artery stenting. This 
may potentially be achieved by technical advances (route of access, stent design and new protection 
devices) and increased operator skill. However, more data from randomised trials to evaluate these 
new devices and access routes are needed. Our finding that age is associated with both immediate and 
delayed procedural events in the stenting group argues against vascular anatomy as the sole mediating 
factor. Other, currently unknown factors are likely to contribute to this effect and remain to be 
elucidated. 
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Figures 
 
Figure 13 - Study flow chart.  
 
Study flow chart depicting all patients in trials included in meta-analysis as well as events that 
precluded them from analysis.  
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Figure 14 - Kaplan-Meier curve.  
 
Kaplan-Meier curve of the cumulative incidence of periprocedural stroke or death within 30 days after 
treatment in the stenting and endarterectomy group seperately. Number of events: 169 events in the 
CAS group, 87 events in the CEA group. The cumulative incidence of stroke or death was 7.3% in the 
CAS group and 3.9% in the CEA group. 
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Figure 15 - Effects of baseline variables on the risk of stroke or death in patients treated with carotid 
artery stenting.  
 
Forest plot showing the odds ratios for the effects of the three baseline variables patient age (in 
decades), any history of smoking, and qualifying event severity on the incidence of stroke or death on 
the day of treatment (day 0), between day 1 and 30, or within 30 days in patients treated with stenting. 
ORs were estimated by three separate GLMMs (one for the day of treatment, one for day 1- 30, and 
one for the full procedural period), each containing age, any history of smoking, and QE severity (stroke 
> TIA > ocular ischaemia). CI=Confidence Interval; OR=Odds Ratio; QE=Qualifying event; 
GLMM=general linear mixed model.  
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Figure 16 - Effects of baseline variables on the risk of stroke or death in patients treated with carotid 
endarterectomy.  
 
Forest plot showing the odds ratios for the effects of the baseline variable “mRS at baseline”,  and 
history of hypertension on the incidence of stroke or death on the day of treatment (day 0), between 
day 1 and 30, or within 30 days in patients treated with endarterectomy. ORs were estimated by three 
separate GLMMs (one for the day of treatment, one for day 1-30, and one for the full procedural 
period). OR=Odds ratio; CI=confidence interval; GLMM=general linear mixed model; mRS=modified 
Rankin scale 
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Tables 
 
Table 2 - Patient characteristics at baseline. 
  
CEA 
(n = 2271) 
CAS 
(n = 2326) 
Male n (%) 1593/2271 (70.1%) 1615/2326 (69.4%) 
Age years (mean, SD) 69.4 ± 9.2 69.2 ± 9.2 
Systolic blood pressure mmHg (mean, SD) 142.8 ± 21 143.9 ± 21 
Hypertension n (%) 1718/2264 (75.9%) 1743/2264 (75.3%) 
Diabetes n (%) 576/2270 (25.4%) 575/2325 (24.7%) 
Hyperlipidaemia* or LLT n (%) 1471/2271 (64.7%) 1462/2326 (62.9%) 
LLT 1443/2271 (63.5%) 1439/2326 (61.9%) 
Smoking (current or past) n (%) 1472/2254 (65.3%) 1489/2308 (64.5%) 
Coronary artery disease n (%) 630/2218 (28.4%) 626/2276 (27.5%) 
mRS at baseline n (%) 
0 n (%) 1133/2252 (50.3%) 1167/2305 (50.6%) 
1 n (%) 587/2252 (26.1%) 622/2305 (27.0%) 
2 n (%) 365/2252 (16.2%) 358/2305 (15.5%) 
>2 n (%) 167/2252 (7.4%) 158/2305 (6.9%) 
Degree of ipsilateral carotid stenosis 
Moderate (50-69%) n (%) 443/2271 (19.5%) 441/2326 (19%) 
Severe (70-99%) n (%) 1828/2271 (80.5%) 1885/2326 (81.0%) 
Contralateral stenosis or occlusion 301/2037 (14.8%) 308/2326 (14.8%) 
Qualifying event type 
Ocular ischaemia n (%) 388/2256 (17.2%) 394/2312 (17.0%) 
Transient ischaemic attack n (%) 835/2256 (37.0%) 847/2312 (36.6%) 
Hemispheric stroke n (%) 1033/2256 (45.8%) 1071/2312 (46.3%) 
Days from QE to treatment median (IQR)† 29.0 (13.0, 67.0) 26.0 (11.0, 61.0)  
Treatment within 7 days of QE n (%) † 214/1907 (11.2%) 277/1926 (14.4%) 
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Baseline data of patients in the stenting and endarterectomy group. Percentages exclude missing data. 
CEA = carotid endarterectomy; CAS = carotid artery stenting; LLT = lipid lowering therapy: EVA-3S 
recorded LLT use at baseline but patients were only considered to be taking LLT if started >3months 
prior to randomisation. SPACE and CREST collected data on LLT use at randomisation. ICSS did not 
collect information on LLT use at baseline but did collect these data at the one-month follow-up, which 
were included in the table. QE = qualifying event; SD = standard deviation.*Data were not collected in 
SPACE. †Date of the qualifying event before randomisation was not collected in the SPACE trial initially, 
but for the pooled analysis, these dates were gathered where available. 
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Table 3 - Outcome events occurring on the day of procedure vs. day 1-30 thereafter. 
 CAS 
(n=2326) 
CEA 
(n=2271) 
Total 
(n=4597) 
 Day of procedure Day 1-30 Day of procedure Day 1-30 Day of procedure Day 1-30 
Any stroke n(%) 109  52 42 43 151 95 
Ipsilateral  100 (92%) 47 (90%) 42 (100%) 37 (86%) 142 (94%) 84 (88%) 
Non-ipsilateral  9 (8%) 5 (10%) 0 (0%) 6 (14%) 9 (6%) 11 (12%) 
Ischaemic stroke n (%) 108 (99%) 48 (92%) 41 (98%) 32 (74%) 149 (99%) 80 (84%) 
Haemorrhagic stroke n (%) 1 (1%) 4 (8%) 1 (2%) 11 (26%) 2 (1%) 15 (16%) 
Non-stroke death  1 7 0 3 1 10 
 
Data are numbers and percentages of patients who experienced an outcome event. CAS = carotid artery stenting; CEA = carotid endarterectomy. 
 
 
 
 
72 
 
6.4. Project 4 - Secular trends in procedural stroke or death risks of stenting 
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Abstract 
 
Background- Over the past decades, stroke risk associated with carotid disease has decreased, 
reflecting improvements in medical therapy and a more rigorous control of vascular risk factors. It is 
less clear whether the procedural risk of carotid revascularization has declined over time.  
Methods and Results - We analysed temporal changes in procedural risks among 4,597 patients with 
symptomatic carotid stenosis treated with carotid artery stenting (CAS; n=2,326) or endarterectomy 
(CEA; n=2,271) in 4 randomised trials between 2000 and 2008, using generalized linear mixed-effects 
models with a random intercept for each source trial. Models were additionally adjusted for age and 
other baseline characteristics predicting treatment risk. The primary outcome event was any 
procedural stroke or death, occurring during or within 30 days after revascularization. The procedural 
stroke or death risk decreased significantly over time in all patients (unadjusted OR per year 0.91, 95% 
CI 0.85-0.97, p=0.006). This effect was driven by a decrease in the CEA group (unadjusted OR per year 
0.82, 95% CI 0.73-0.92, p=0.003), whereas no significant decrease was found after CAS (unadjusted OR 
0.96, 95% CI 0.88-1.04, p=0.33). CEA patients had a lower procedural stroke or death risk compared to 
CAS patients, and the difference significantly increased over time (interaction p=0.031). After 
adjustment for baseline characteristics, the results remained essentially the same.  
Conclusions - The risk of stroke or death associated with carotid endarterectomy for symptomatic 
carotid stenosis decreased over an 8-year period, independent of clinical predictors of procedural risk. 
No corresponding reduction in procedural risk was seen in patients treated with stenting.  
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Introduction 
 
Over the past decades the risk of stroke associated with carotid disease appears to have decreased,102 
reflecting improved medical care and risk factor control. In some patients, the risk of stroke under 
conservative management may be so low that the risks associated with carotid revascularisation are 
no longer justified. This is of relevance for patients with asymptomatic carotid stenosis but potentially 
also for patients with symptomatic carotid stenosis. On the other hand, the procedural risk associated 
with carotid revascularisation may also have decreased over time preserving the net benefit of invasive 
treatment. The evidence to support or refute such a trend is currently limited.  
 
We conducted an analysis of the temporal change in procedural stroke or death risks associated with 
CEA and CAS in four large randomised controlled trials which enrolled patients with symptomatic 
carotid stenosis between 2000 and 2008, using data at individual patient level.63, 64, 66, 67 We 
hypothesized that procedural risks associated with carotid artery revascularisation would have 
declined over time. In addition, we assumed that risks of CAS might have decreased more strongly than 
CEA risks, due to technical development and increasing experience.  
 
Methods 
 
This meta-analysis includes individual patient data from EVA-3S (NCT 00190398), SPACE (ISRCTN 
57874028), CREST (NCT00004732) and ICSS (ISRCTN 25337470) and is based on the same dataset as 
Project 3 (section 6.3.)63, 64, 66, 67 The present analysis was pre-specified during one of the regular 
steering committee meetings of the Carotid Stenosis Trialists’ Collaboration by representatives from 
the involved trials. All four trials randomly allocated patients with symptomatic moderate to severe 
carotid stenosis (≥50% reduction of lumen diameter measured according to the method used in the 
NASCET34), who were equally suitable for either procedure to CAS or CEA. CREST additionally included 
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patients with asymptomatic carotid stenosis, but these patients were excluded from the present 
analysis.  
In EVA-3S, SPACE and ICSS any stent with a CE (Communauté Européeene) mark could be used. In 
CREST the protocol specified the use of RX Acculink stent. In EVA-3S the use of distal filter protection 
devices became mandatory early in the trial.103 In CREST, the protocol specified the use of the RX 
Accunet embolic-protection device whenever feasible. In ICSS and SPACE the use of protection devices 
remained optional throughout the trials. Surgeons were allowed to perform standard or eversion 
endarterectomy under local or general anaesthesia, with or without the use of shunts or patches.  
 
The primary outcome of the present analysis was any stroke or death occurring within 30 days after 
treatment. Stroke was defined as an acute deficit of focal neurological function, which led to symptoms 
lasting longer than 24 hours, resulting from intracranial vascular disturbance (ischaemia or 
haemorrhage).  
 
Statistical analysis 
 
The analysis population included all patients in whom the randomly allocated treatment was initiated 
(per-protocol analysis).61 The following baseline characteristics of patients from all 4 source trials were 
summarized descriptively for an early (2000-2004) and a late enrolment period (2005-2008): sex, 
patient age, modified Rankin Scale (mRS) at baseline, systolic blood pressure at baseline, history of 
hypertension, diabetes, lipid-lowering therapy (LLT), smoking (past or present), coronary heart disease, 
degree of ipsilateral carotid stenosis according to NASCET criteria6, presence of contralateral carotid 
stenosis (≥70%) according to NASCET criteria6 or occlusion, qualifying event (QE) type, and days from 
QE to treatment. 
 
To investigate whether the risk of stroke or death within 30 days of treatment changed over time, we 
used GLMMs with binomial error and logit link function, with a random intercept for each source trial. 
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We fitted one GLMM for all patients, using treatment received (CAS vs. CEA), year of treatment (as 
continuous variable) and the interaction between treatment received and year of treatment as 
explanatory variables to investigate if any difference in procedural risk between CAS and CEA changed 
over time. In addition, a separate GLMM with only year of treatment as explanatory variable was fitted 
for each treatment group separately. To adjust our models, we identified those baseline patient 
characteristics which were most strongly associated with procedural risk for stroke or death, using 
backward model selection based on Akaike’s information criterion (AIC), in all patients and in each 
treatment group separately. We continued dropping variables from the multivariate models as long as 
the AIC for the reduced model was smaller than the AIC of the former model. Due to the high 
percentage of missing values, we did not include days from QE to treatment in the backward model 
selection. The models investigating the effect of time on procedural risk were subsequently adjusted 
for all baseline characteristics selected in this manner. We performed a post-hoc sensitivity analysis 
adjusting all models for days from QE to treatment. 
 
Results  
 
In total, 4,775 patients with symptomatic carotid stenosis were enrolled in the contributing trials. The 
pooled per-protocol analysis set included 4,597 patients, 2,271 of whom received CEA and 2,326 CAS 
(Figure 13, section 6.3). EVA-3S enrolled patients from 2000-2005, SPACE from 2001-2006, ICSS from 
2001-2008, and CREST from 2000-2008. Baseline characteristics were well balanced between 
treatment groups as previously reported.63, 64, 66, 67 The proportions of patients with a history of 
hypertension, coronary heart disease, smoking and severe ipsilateral carotid stenosis were significantly 
higher in the later enrolment period (2005-2008) compared to the early enrolment period (2000-2004; 
Table 4). The proportion of patients taking LLT significantly increased from 52.4% in the early 
enrolment period to 74.1% in the late enrolment period. Level of functional disability measured by the 
mRS was higher and the time from QE to treatment was shorter in the late enrolment period (Table 
4). 
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Crude percentages of patients with the primary outcome measure per year are shown in Table 5. In 
the CEA group, crude procedural risks were 7.1% between 2000-2002 and 2.0% between 2007-2008. 
In the CAS group, crude risks were 8.2% between 2000-2002 and 5.8% between 2007-2008 (Table 5). 
The risk of stroke or death during the procedural period for both treatments combined decreased 
significantly over time (unadjusted OR per year 0.91, 95% CI 0.85-0.97, p=0.006). After adjustment for 
baseline characteristics which were independently associated with the primary outcome in both 
treatment groups combined (age, mRS, hypertension, diabetes, and severe ipsilateral carotid stenosis), 
the decline in risk remained essentially unchanged (adjusted OR 0.89, 95% CI 0.83-0.95, p<0.001). In 
the post-hoc sensitivity analysis additionally adjusting our models for days from QE to treatment, the 
results remained again essentially the same (OR 0.91, 95% CI 0.84-0.99, p=0.023).  
 
In the CEA group alone, the risk of procedural stroke or death also decreased significantly over time, 
both in the unadjusted model (OR 0.82, 95% CI 0.73-0.92, p=0.003), in the model adjusted for mRS, 
hypertension, diabetes, coronary heart disease, ipsilateral severe carotid stenosis, and contralateral 
stenosis >50% or occlusion ( OR 0.82, 95% CI 0.72-0.93, p=0.002), and in the model additionally 
adjusted for days from QE to treatment (OR 0.81, 95% CI 0.71-0.93, p=0.005). 
 
In the CAS group alone, the change in procedural risk over time was not statistically significant in the 
unadjusted model (OR 0.96, 95% CI 0.88-1.05, p=0.33), in the model adjusted for age, hypertension, 
LLT, smoking, and qualifying event type (OR 0.95, 95% CI 0.87-1.05, p=0.28), nor in the model 
additionally adjusted for days from QE to treatment (OR 0.95, 95% CI 0.86-1.06, p=0.38). 
Patients receiving CEA were at lower risk of procedural stroke or death than patients receiving CAS 
over the entire enrolment period (OR 0.47, 95% CI 0.35-0.62, adjusted for year of treatment; OR 0.46, 
95% CI 0.35-0.62, adjusted for year of treatment, age, mRS at baseline, history of hypertension and 
diabetes, severe ipsilateral carotid stenosis). This difference in procedural risk became more 
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pronounced over time (unadjusted interaction: OR 1.17, 95% CI 1.02-1.35, p=0.031, adjusted 
interaction: OR 1.16, 95% CI 1.01-1.34, p=0.038; Figures 17 and 18). The interaction was of similar 
magnitude but no longer statistically significant when additionally adjusting for days from QE to 
treatment (OR 1.13, 95% CI 0.96-1.34, p=0.142). 
 
Discussion 
 
In this meta-analysis of individual patient data from 4 RCTs, the risk of stroke or death associated with 
carotid revascularization for symptomatic carotid stenosis decreased significantly over time. When 
patients were analysed separately by treatment, the decline in risk over time was only statistically 
significant in patients treated with carotid endarterectomy. This decrease in risk was independent of 
clinical risk factors.  
 
Data from the Oxford Vascular Study (Oxvasc) showed a decline in age and sex specific stroke incidence 
in an unselected population in Oxfordshire, UK between 1981-84 and 2002-04,104 coinciding with a 
significant increase in the use of blood pressure lowering, antiplatelet and lipid-lowering medication 
between the two periods. Likewise, meta-regression analyses suggested a decline in annual stroke risk 
associated with asymptomatic carotid stenosis over the past 20 years.102 Indirect evidence on a decline 
in stroke risk in patients with symptomatic carotid stenosis can be gathered from TIA registries: the 
90-day stroke risk after a TIA caused by large artery atherosclerosis was consistently reported to be 
around 20% in the last decade, 105, 106 but dropped to merely 6% in a recent publication.107 While some 
of this decrease may probably have been accounted for by more rapid specialized assessment and 
early carotid revascularization in selected patients, changes in medical therapy are also likely to be 
important. A study from Denmark of patients with symptomatic carotid stenosis found a decline in the 
rate of any recurrent cerebrovascular event prior to carotid revascularization from 29% to 2.5% after 
introduction of an optimized medical treatment regimen consisting of dual antiplatelet and statin 
therapy.108 
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In the original European and North American symptomatic carotid endarterectomy trials establishing 
the benefit of CEA in patients with symptomatic carotid stenosis, only a minority of patients received 
statins.8 Since these trials were conducted, medical therapy and risk factor management has improved, 
not only with more widespread use of statins but also with stricter control of blood pressure and 
management of other risk factors. A lower stroke risk under conservative management than observed 
in previous trials may obviate the need for invasive revascularization in many patients with 
symptomatic or asymptomatic carotid disease. On the other hand, any decline in the procedural risk 
of stroke or death associated with carotid revascularization would act towards maintaining the net 
benefit of invasive treatment. Existing literature suggests a decline in procedural risk associated with 
CEA for asymptomatic carotid stenosis. 109 However, reliable data on procedural risks for symptomatic 
carotid stenosis have been sparse,110 and it remained unknown if temporal changes differed between 
CAS and CEA.  
 
Our findings now provide strong evidence for a decline in procedural stroke or death risk associated 
with revascularization of symptomatic carotid stenosis over time. The availability of data at individual 
patient level from several randomised clinical trials yielded important strengths. First, we were able to 
show temporal changes with greater statistical power than was possible at the level of a single trial. 
Second, we were able to minimize the risk of confounding of the effect of time on procedural risk by a 
potential change in the characteristics of patients included in the trials during the course of enrolment. 
Some of the baseline risk factors which were associated with the procedural risk of stroke or death in 
both treatment groups combined (history of hypertension, disability measured by the mRS, and degree 
of ipsilateral carotid stenosis) became more prevalent in the later enrolment period. After adjusting 
for these risk factors, the results remained essentially the same.  
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A third strength of our study was that we were able to investigate whether any temporal trend in 
procedural risks would differ between CEA and CAS, owing to the randomised design of the source 
trials. Wide-spread use of CAS only started a few years before the start of the trials contributing to this 
meta-analysis. We therefore hypothesized that technical development and increasing experience 
would lead to a stronger decline in procedural risk with CAS compared to CEA. Surprisingly, we found 
the opposite to be true.  It is possible that investigators became more selective in the patients they 
included in the trials as enrolment went on, in terms of characteristics that were not measured. If this 
was the case, any such selection effect must have had a stronger impact on procedural risks of CEA 
than on risks of CAS. Previous studies suggest that neurophysiological monitoring and intra-operative 
assessment of the treated carotid artery during the CEA procedure became more frequent over time 
and that these factors are associated with a lower short-term stroke or death risk.111, 112 It is possible 
that these factors were also of importance in our study population, but the data were not available for 
the present analysis. For CAS however, with growing experience, interventionists might have accepted 
patients in the trials with more difficult anatomy, which may have counteracted any learning-curve 
effect. 
 
The CREST investigators have previously reported a non-significant decline in the procedural stroke or 
death risk associated with CAS over time, and an initial decrease followed by an increase in CEA risk 
for which there was no conclusive explanation.113 Of note, CREST initially included only patients with 
symptomatic carotid stenosis, but then additionally allowed patients with asymptomatic carotid 
stenosis in the trial during the course of enrolment. This change in the proportion of the two groups 
limited the investigation of a temporal trend. In the present, pooled analysis, only patients with 
symptomatic carotid stenosis were included from the CREST trial. The combined analysis of data from 
four trials allowed for a more reliable investigation of temporal changes in treatment risks, and 
whether these differed between CAS and CEA, than was possible at the level of a single trial. 
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The question whether any change in procedural risk of carotid revascularization over time would be 
explained by an increased use of lipid-lowering therapy was of particular interest. We found an 
increase of patients taking LLT from 52% in the early enrolment years to 74% in the late enrolment 
years. However, LLT did not explain procedural risk in the entire study population or in patients treated 
with CEA. LLT reduced procedural risk in patients treated with CAS but the temporal change in CAS risk 
was not statistically significant either unadjusted or adjusted for LLT and other risk factors. 
 
As both risk of stroke and procedural risk of revascularisation appear to be lower than at the time of 
the initial CEA trials, substantial uncertainty remains as to which patients will still benefit from carotid 
revascularization in addition to contemporary medical therapy and risk factor management. Several 
randomised trials are currently investigating this question, including the Second European Carotid 
Surgery Trial (ECST-2), the Stent Protected Angioplasty versus Carotid Endarterectomy Trial 2 (SPACE-
2), the Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial 
(CREST-2), and the Endarterectomy Combined with Optimal Medical Therapy (OMT) vs OMT Alone in 
Patients With Asymptomatic Severe Atherosclerotic Carotid Artery Stenosis at Higher-than-average 
Risk of Ipsilateral Stroke (ACTRIS) trial.  
 
Our study has important limitations. First, the trials included in this meta-analysis were conducted 
between 2000 and 2008. The procedural risk associated with carotid revascularization methods might 
have declined even further since 2008. Particularly in CAS, the most recent technical developments, 
such as stent designs with very small open area between struts,114 reverse-flow protection systems,48 
and direct trans-cervical access115 were only achieved after completion of the 4 trials included in this 
meta-analysis and many devices used in these trials are now outdated and now longer in use. Second, 
in the earliest years of enrolment (2000-2002) most patients included in this analysis were enrolled in 
either EVA-3S or SPACE. In addition, between 2007 and 2008 enrolment only continued in ICSS and 
CREST while EVA-3S and SPACE had completed their enrolment. However, the adjustment for source 
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trial included in all of our models should account for any differences between trials. In addition, in a 
post-hoc analysis in which we excluded all patients from EVA-3S, the results remained essentially 
unchanged. Third, the results obtained in this analysis cannot necessarily be extrapolated to a decline 
in procedural risk outside of clinical trials. Fourth, due to the high percentage of missing values, we did 
not include days from QE to treatment in our initial analysis even though this variable was shown to 
differentially influence the risk of carotid revascularization.116 
 
Conclusions 
 
Treatment of symptomatic carotid stenosis within the examined trials became safer over time. The 
reduction in stroke or death risk over time was driven by a significant decline in procedural risks in 
patients treated with endarterectomy. Mechanisms underlying these findings remain to be 
determined. 
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Figures 
 
Figure 17 - Decline in risk of stroke or death over time – unadjusted model. 
 
Modelled risks of stroke or death occurring within 30 days after treatment over time by treatment 
group in the unadjusted generalized linear mixed-effects model. Open and closed circles represent 
fitted values from the model. Error bars represent Bayesian 95% credible intervals. The interaction 
between type of treatment and year of treatment was statistically significant (interaction p=0.031). 
CEA – carotid endarterectomy; CAS – carotid artery stenting. 
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Figure 18 - Decline in risk of stroke or death over time – adjusted model. 
 
Modelled risks of stroke or death (fitted values) occurring within 30 days after treatment over time by 
treatment group in the adjusted generalized linear mixed-effects model. The fitted values are shown 
for a “model patient” with median age and modified Rankin Scale (mRS) score at baseline, history of 
hypertension and severe carotid stenosis, but no history of diabetes mellitus. Open and closed circles 
represent fitted values from the model. Error bars represent Bayesian 95% credible intervals. The 
interaction between type of treatment and year of treatment was statistically significant (interaction 
p=0.038). CEA – carotid endarterectomy; CAS – carotid artery stenting. 
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Tables  
 
Table 4 - Baseline characteristics in the early (2000-2004) and late (2005-2008) enrolment period. 
 
2000-2004 
(n = 2,044) 
2005-2008 
(n = 2,553) 
p-value 
Male sex 69.8% 69.8% ns 
Age, years (mean, SD) 69.2 ± 9.4 69.3 ± 9.1 ns 
Systolic blood pressure at baseline, mmHg 
(mean, SD) 
143.7 ± 19.8 143.1 ± 21.9 ns 
Hypertension 73.8% 77.0% 0.016 
Diabetes 25.8% 24.4% ns 
LLT* 52.4% 74.1% <0.001 
Smoking (current or past) 62.0% 67.3% <0.001 
Coronary heart disease 26.2% 29.3% 0.025 
mRS at baseline (median [IQR]) 0 (0-1) 1 (0-1) 0.02 
Degree of ipsilateral carotid stenosis  <0.001 
Moderate (50-69%) 22.4% 16.7%  
Severe (70-99%) 77.6% 83.3%  
Contralateral stenosis or occlusion 14.5% 15.0% ns 
Qualifying event type  ns 
Retinal ischaemia 15.7% 18.3%  
Transient ischaemic attack 37.9% 36.0%  
Hemispheric stroke 
 
46.4% 45.8%  
Days from qualifying event to treatment 
(median [IQR])† 
32 (15-68) 26 (11-61) <0.001 
 
Baseline characteristics of patients enrolled in the 4 source trials during the early enrolment period 
(2000-2004) and the late enrolment period (2005-2008). P-values for differences in baseline 
characteristics between the early and the late enrolment period were calculated using Welch test for 
continuous variables, Wilcoxon rank sum test for mRS (not normally distributed), and Chi-squared test 
for categorical variables. SD indicates standard deviation, mRS: modified Rankin Scale, ns: not 
significant. *LLT: lipid-lowering therapy: EVA-3S recorded LLT use at baseline but patients were only 
considered to be taking LLT if started >3months prior to randomisation. SPACE and CREST collected 
data on LLT use at randomisation. ICSS did not collect information on LLT use at baseline but did collect 
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these data at the one-month follow-up, which were included in the table. † Date of the qualifying event 
before randomisation was not collected in SPACE initially, but for the pooled analysis, these dates were 
gathered where available. As a result, 16.6% of values for this variable are missing. 
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Table 5 - Procedural risk for stroke or death expressed as crude risks over time. 
Year of treatment All patients 
(n = 4,597) 
Endarterectomy 
(n = 2,271) 
Stenting 
(n = 2,326) 
N Patients N (%) N Patients N (%) N patients N (%) 
2000-2002 n (%) 560 43 (7.7%) 280 20 (7.1%) 280 23 (8.2%) 
2003 n (%) 659 43 (6.5%) 330 18 (5.5%) 329 25 (7.6%) 
2004 n (%) 825 37 (4.5%) 411 13 (3.2%) 414 24 (5.8%) 
2005 n (%) 919 58 (6.3%) 439 14 (3.2%) 480 44 (9.2%) 
2006 n (%) 630 37 (5.9%) 310 13 (4.2%) 320 24 (7.5%) 
2007-2008 n (%) 1004 39 (3.9%) 501 10 (2.0%) 503 29 (5.8%) 
Total 4597 257 (5.6%) 2271 88 (3.9%) 2326 169 (7.3%) 
 
Total numbers of patients recruited, as well as numbers of patients and crude percentages of patients with the primary outcome measure per year for all patients, 
patients treated with endarterectomy and patients treated with carotid stenting separately. The years 2000-2003 and 2007-2008 were pooled due to the relatively 
small number of patients enrolled. 
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7. Discussion and Outlook 
 
The aim of this PhD thesis was to contribute towards enabling personalised treatment decisions for 
patients with carotid disease by comparing procedural risks and long-term effects of carotid stenting 
and endarterectomy in patients with symptomatic and asymptomatic carotid stenosis and to explore 
parameters specifically linked to the mechanisms of stroke occurring as a complication of carotid 
revascularisation procedures.  
7.1. Procedural risks and long-term effects of carotid artery stenting and 
endarterectomy 
 
To gain a comprehensive overview of the available randomised evidence on treatment of carotid 
stenosis, we first updated a systematic Cochrane Review including all new evidence, which had become 
available since the last update in 2012.  The main results of this systematic review were that among 
patients with symptomatic carotid stenosis, CAS carries a higher risk of procedure related stroke or 
death than CEA.61 The extra procedural risk associated with CAS is mostly attributed to an increase in 
minor, non-disabling strokes. In contrast, the risks for myocardial infarction, cranial nerve palsy and 
access site hematoma are higher with CEA than with CAS. Beyond the procedural period, both 
treatments are equally effective at preventing recurrent stroke or severe restenosis of the treated 
artery. For patients with asymptomatic carotid stenosis, high-level evidence is still limited, but suggests 
that there may also be a small increase in procedure related stroke with CAS compared to CEA. 
Thus, the available evidence clearly demonstrates that given the equal long-term durability of CAS and 
CEA, the choice between the two procedures in individual patients should primarily be informed by 
minimising procedural risks. We therefore focussed our further research in this PhD programme on 
risk factors and mechanisms associated with procedure related stroke or death and how these risk 
factors would influence the relative risk of these complications between CAS and CEA. 
 
89 
 
7.2. Personalised treatment: age and sex 
 
Our subgroup analyses performed as part of the Cochrane Review revealed that increasing patient age 
is an important risk factor for procedure related stroke or death in CAS. The risk of death or any stroke 
in the short-term is similar between CAS and CEA in patients younger than 70 years. In patients who 
are 70 years or older however, the risk of death or any stroke is significantly higher with CAS than CEA.  
In contrast, treatment effects were similar in men and women. 
Thus, CAS is a safe and effective treatment alternative to CEA for patients younger than 70 years. 
Patients who are 70 years or older should primarily be treated with CEA. However, there is currently 
no evidence that the treatment recommendation on the choice of CAS or CEA should differ between 
men and women.  
The mechanisms mediating the interaction between patient age and procedural risk in CAS are 
currently poorly understood. A discussion of possible underlying mechanisms is provided in section 7.3 
and 7.4. of this thesis. 
7.3. Personalised treatment: vascular anatomy 
 
In order to prevent procedural complications occurring during CAS and CEA, further knowledge on 
patient-related risk factors (other than patient age) potentially increasing the risk of complications was 
needed. Navigation of the endovascular catheter in the vascular tree during CAS may dislodge emboli, 
which might cause distal embolization and stroke. This might be particularly relevant in patients with 
difficult configuration of the aortic arch or tortuous supra-aortic vessels.  
We therefore systematically assessed vascular anatomy in patients with symptomatic carotid stenosis 
randomised to CAS or CEA within the ICSS-MRI substudy. We were able to confirm our hypothesis that 
complex vascular anatomy increases the risk for cerebral ischaemia during CAS but not during CEA. 
Owing to the use of new DWI lesions on brain MRI as a surrogate outcome measure, we were able to 
increase the power of our analysis which allowed us to investigate this important research question 
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despite the comparatively time consuming method used for the systematic assessment of vascular 
anatomy. Our findings are particularly relevant as our assessment of vascular anatomy was performed 
on baseline MR- and CT-angiography, which are commonly obtained during routine diagnostic work-
up in patients with carotid disease before treatment is initiated.  
The results of our update of the Cochrane Review and further previous research had identified older 
age as an important risk factor for procedural stroke in CAS.74 Elongation of the aortic arch and supra-
aortic arteries were found to be more prevalent in elderly patients. Hence the increased risk of 
procedural stroke in elderly patients might be mediated by vascular anatomy. However in our analysis, 
the association between complex vascular anatomy and cerebral ischaemia in CAS remained significant 
even after correction for age. Thus, complex vascular anatomy seems to be an important risk factor 
for procedural cerebral ischaemia in CAS independent of the patient’s age and should be taken into 
account when selecting the optimal treatment option for the individual patient.    
7.4. Timing of procedural risks 
 
In order to prevent procedural complications of CAS and CEA, further knowledge was needed on their 
temporal distribution and associated risk factors. We therefore conducted an individual patient-data 
meta-analysis pooling data from four randomised controlled trials comparing CAS versus CEA in 
symptomatic patients (EVA-3S, SPACE, ICSS and CREST) to investigate the timing of stroke or death 
within the 30-day peri-procedural period. We found that the increased occurrence of procedural 
stroke or death in patients treated with CAS was limited to the day of treatment. For the remainder of 
the peri-procedural period (day 1-30 after treatment), there was no significant difference in the 
occurrence of stroke or death between the two treatments. These findings confirm the assumption 
that the majority of complications occur on the day of the revascularisation procedure. Hence, 
technical improvements and increased operator skill could potentially lower the procedural risk 
associated with CAS. Importantly, since the trials included in our meta-analysis were conducted, CAS 
technology has evolved considerably (alternative access routes, e.g. direct carotid access, newer 
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protection devices, e.g. flow-reversal, and new stent devices, e.g. membrane covered stents). 
However, randomised evidence on the benefit of these advances is sparse and it remains to be shown 
whether CAS using current technologies carries a similar risk to CEA in patients with symptomatic 
carotid stenosis.  
Of note, we identified patient age as an important risk factor for both immediate and delayed stroke 
or death in the CAS group. This finding argues against vascular anatomy as the sole mediating factor 
between age and procedural stroke in CAS. Another possible underlying mechanism mediating this 
association might be that older patients have more unstable atheromatous lesions than younger 
patients, which may cause thromboembolic strokes not only on the day of treatment, but also during 
the following days. However, further research elucidating the association between patient age and 
procedural risk in CAS is needed. 
7.5. Secular trends of procedural risks  
 
Owing to improved medical management and better control of vascular risk factors, the risk of stroke 
under contemporary medical therapy in patients with carotid disease is lower than in the early trials 
establishing the benefit of CEA compared with medical therapy alone.102 This raises the question, 
whether patients with carotid stenosis at low or intermediate risk of stroke still benefit from carotid 
revascularisation procedures. On the other hand, any decline in the procedural risk of stroke or death 
associated with CAS and CEA would act towards maintaining the net benefit of invasive treatment. We 
therefore analysed temporal changes in procedural risk associated with CAS and CEA within a second 
analysis of the same, pooled dataset of individual patients.  
Our analysis revealed that the risk of stroke or death associated with carotid revascularisation 
procedures has decreased over time. The decline in procedural risk was particularly apparent in 
patients treated with CEA, while we found no significant decrease in patients treated with CAS. 
Widespread use of CAS only began a few years prior to the start of the trials contributing to our meta-
analysis. We had therefore hypothesized that technical development and increased experience with 
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this comparatively new procedure would result in a stronger decline in procedural risk in CAS 
compared with CEA. Surprisingly, we found the opposite to be true.  
Our findings provide strong evidence that invasive treatment of symptomatic carotid stenosis has 
become safer over time. This supports the notion that patients with symptomatic carotid stenosis may 
still benefit from carotid revascularisation procedures, even though stroke risk associated with carotid 
disease has declined. However, currently ongoing randomised trials will ultimately answer the 
question whether patients with carotid disease, who are at low to intermediate risk of stroke and 
receive contemporary medical therapy as well as risk factor control, still benefit from carotid 
revascularisation. These trials include the Second European Carotid Surgery Trial (ECST-2) which 
compares revascularisation by endarterectomy or stenting combined with optimal medical therapy 
(OMT) versus OMT alone in patients with asymptomatic or low-to-intermediate risk symptomatic 
carotid stenosis. A specific carotid artery risk score is used to quantify the risk for recurrent stroke in 
patients with symptomatic carotid stenosis and identify patients eligible to participate. Other currently 
ongoing randomised trials include the Carotid Revascularization and Medical Management for 
Asymptomatic Carotid Stenosis Trial (CREST-2)117 and the Endarterectomy Combined with Optimal 
Medical Therapy (OMT) vs OMT Alone in Patients With Asymptomatic Severe Atherosclerotic Carotid 
Artery Stenosis at Higher-than-average Risk of Ipsilateral Stroke (ACTRIS) trial.118 
7.6. Outlook and future projects 
 
7.6.1. Vascular anatomy in mechanical thrombectomy for acute ischaemic stroke 
 
Complex anatomy of the supra-aortic vessels might influence the duration of transfemoral 
endovascular treatment for large vessel occlusion in acute ischaemic stroke.119-121 Translating our 
findings from Project 2 (section 6.2.) of this thesis and in collaboration with the Department of 
Neuroradiology, we hypothesized that elongation of the aortic arch, aortic arch variants, and increased 
tortuosity of the supra-aortic arteries result in increased technical difficulty and prolongation of 
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mechanical thrombectomy for acute ischaemic stroke. This may subsequently result in a clinically less 
favourable outcome. 
We performed a retrospective analysis of all patients who have undergone mechanical thrombectomy 
for acute large vessel occlusion at the University Hospital Basel between January 2014 and December 
2017 and systematically assessed the anatomy of the aortic arch and the supra-aortic vessels as 
described in Project 2 (section 6.2.) of this thesis.  
The primary outcome measure is the duration of the intra-arterial mechanical thrombectomy 
procedure. Secondary outcome measures include the time from femoral artery puncture to time of 
revascularisation, focal neurological deficits measured according to the National Institute of Health 
Stroke Scale (NIHSS)122 at 24 hours compared to NIHSS on admission, and functional disability 
measured with the modified Rankin Scale (mRS)58 at 3 months. 
Data collection will be finished by the end of this PhD. We plan to perform statistical analysis and to 
publish our results in 2019. 
7.6.2. Proteomics discovery approach to identify candidate biomarkers of 
atherosclerotic plaque instability 
 
The primary mechanism underlying cerebral ischaemia caused by carotid disease is plaque rupture and 
subsequent embolism to the brain. This has fostered the concept of the unstable or high-risk plaque, 
which is prone to rupture and cause ischaemic stroke. Previous research has shown that high-risk 
plaques associated with ipsilateral stroke can be identified with imaging techniques.123-125 Plaques 
showing intra-plaque haemorrhage (IPH) on MRI are associated with an increased risk of cerebral 
ischaemia compared with plaques without IPH.126, 127  Of note, the presence of IPH on MRI is a much 
stronger predictor of stroke risk than established clinical risk factors such as degree of stenosis or 
symptom status. To date, evidence supporting the use of biomarkers to identify patients with high-risk 
carotid plaques is limited. Comparison of protein expression patterns by proteomics techniques in 
imaging-defined high-risk versus low-risk plaques might provide further insight in biological 
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mechanisms associated with plaque instability and identify potential biomarkers which might be 
clinically valuable in predicting cerebrovascular events. 
In a multicentre cohort study, we aim to study protein expression patterns in endarterectomy 
specimens from patients with symptomatic carotid stenosis who exhibit imaging markers of plaque 
instability and compare those with specimens from patients with asymptomatic carotid stenosis 
without imaging markers of plaque instability.  
The results of this study may help define distinct protein signatures associated with plaque instability, 
which may eventually lead to the discovery of novel serum biomarkers aiding in identifying patients 
with carotid disease at risk of stroke and thus enabling personalised treatment decisions for the 
individual patient. 
MDM has submitted a grant proposal to the Swiss Heart Foundation applying for funding for this 
project.  
7.6.3. Ultrasound plaque imaging and biomarkers 
 
Previous research demonstrated that visualisation of components of the atherosclerotic plaque with 
ultrasound is also possible. On B-mode ultrasound of the carotid artery, parts of the plaque appearing 
dark (echolucent) correspond to necrotic areas with increased lipid content and plaque 
haemorrhage.128 Computerised analysis allows for normalization against reference tissues and 
therefore a quantitative and objective assessment of plaque echolucency, expressed by the grey scale 
median (GSM), i.e. the median grey scale value in the plaque.129 Patients with echolucent plaques are 
at increased risk of stroke.130   
We analysed duplex ultrasound images obtained at baseline in patients with clinically asymptomatic 
carotid stenosis randomised in the ACST-2 MRI substudy and aim to investigate possible associations 
between plaque echolucency, serum biomarkers and the presence of ischaemic brain lesions. Data 
collection for this project is currently still ongoing and is planned to be completed by the end of 2018. 
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7.6.4. Ongoing large randomised controlled trials  
 
7.6.4.1. ACST-2 and ACST-2 MRI substudy 
 
Within ACST-2, patients with asymptomatic carotid stenosis who are deemed to require 
revascularisation are randomly assigned to treatment by CAS or CEA. This large RCT with a planned 
sample size of 3600 patients is scheduled to keep enrolling patients until the end of 2019 and therefore 
lay beyond the scope of this PhD project. Within an MRI substudy patients are examined with 
multimodal MRI of the brain 1-7 days before treatment and 1-3 days after treatment. During this PhD 
project, 76 patients were enrolled at 7 centres worldwide, resulting in 128 patients in total. We plan 
to continue enrolment in the substudy until the end of the main ACST-2 trial in 2019 and aim to publish 
the results of the substudy in 2020. We hypothesise that patients with structural or biological markers 
of plaque instability are at increased risk of cerebral ischaemia occurring during treatment with CAS 
compared with CEA. 
7.6.4.2. ECST-2  
 
Within this large RCT, patients with symptomatic or asymptomatic carotid stenosis in whom there is 
uncertainty about the benefit of revascularisation because they are not at high risk of stroke are 
randomised between optimal medical treatment (OMT) and OMT plus carotid revascularisation by CEA 
or CAS. We hypothesize that carotid revascularisation will reduce the risk of cerebral ischaemia in 
patients in whom structural or biological markers of plaque instability are present, while patients with 
stable plaques experience no additional benefit from revascularisation compared to OMT alone. OMT 
in both arms consists of antiplatelet therapy, statin or other cholesterol lowering treatment, 
antihypertensive treatment if required, and modification of cardiovascular risk factors. 
Imaging of the carotid plaque by multi-contrast MRI and ultrasound, as well as blood samples for 
biomarker analysis are prospectively obtained at baseline in a subset of 244 patients who are enrolled 
in ECST-2. The primary imaging measure for plaque instability is intra-plaque haemorrhage on MRI. 
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Additionally, multimodal MRI scans of the brain are performed at baseline and at a median of 2-year 
follow-up to detect new cerebral infarction or haemorrhage. 
During this PhD 34 patients were enrolled in ECST-2 in Basel. In total, 363 patients were enrolled 
worldwide, 164 of whom had plaque MRI performed at baseline. Recruitment is planned to continue 
until the planned subset sample size of 244 patients is reached.   
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8. Contributions by the PhD student 
 
During my PhD, I had the opportunity to contribute to the planning and conduct of several research 
projects and was able to explore my own research ideas towards the end of my PhD.  
For the update of the Cochrane Review (Project 1, section 6.1.), I performed a systematic review of the 
literature identifying over 8,000 possibly relevant studies, conducted a systematic assessment of data 
quality, extracted outcomes, and performed data synthesis in a meta-analysis. This work provided me 
with the opportunity to learn about rigorous methodology in the conduct of systematic reviews, pitfalls 
and strengths of combining data in a meta-analysis, and with the opportunity to gain a comprehensive 
overview of the available randomised evidence on treatment of carotid stenosis. The skills acquired 
during my work on the Cochrane Review were of great importance for the conduct of the individual 
patient data meta-analyses on the temporal distribution of procedure-related outcome events in CAS 
and CEA and on the development of procedural risk of CAS and CEA over time (Projects 3 and 4, 
sections 6.3. and 6.4.). For these projects, I drafted the statistical analysis plan with the help of a 
statistician, helped with data cleaning, interpreted the statistical results, and wrote the manuscripts.  
For Project 2 (section 6.2.), I contributed to the planning of the study, systematically assessed the 
configuration of the aortic arch, anatomy of the supra-aortic vessels and pre-defined stenosis 
characteristics in all 184 patients included in the analysis, performed statistical analysis, and wrote the 
manuscript.   
Besides my work on our research projects, my responsibilities also consisted of the recruitment, 
randomisation and follow-up of patients in ongoing RCTs of patients with carotid disease (ACST-2, 
ECST-2, PRECISE-MRI). During my PhD, we recruited 86 patients in all three trials combined. I acquired 
the necessary skills to perform carotid duplex ultrasound and subsequently followed all trial patients 
clinically and with duplex ultrasound. During the three years as a PhD student, I performed 
approximately 280 ultrasound examinations.  
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As study coordinator for the ACST-2 MRI substudy, I was the main contact person for issues concerning 
the substudy, managed all participating centres, recruited new centres, and worked closely with the 
Clinical Trial Unit adjusting the electronic database and setting up a screening log. I additionally took 
part in regular Collaborators’ Meetings reporting on the progress of the substudy and helped conduct 
site initiation visits for new centres in Switzerland. I was additionally involved in setting up and 
maintaining a biobank for blood samples obtained as part of our biomarker projects. Moreover, I was 
responsible for collecting and inventorying MRI images obtained at the collaborating centres within 
the ACST-2 MRI substudy.   
During the last year of my PhD, I was involved in the supervision of two Masters Students, both of 
whom are currently working in two of the ongoing research projects (7.6.1. Vascular anatomy in 
mechanical thrombectomy for acute ischaemic stroke and 7.6.3. Ultrasound plaque imaging and 
biomarkers).  
As an original spin-off of our study on the influence of vascular anatomy on the risk of CAS and CEA 
and in collaboration with the Department of Diagnostic and Interventional Neuroradiology, I was able 
to translate our findings into the field of endovascular therapy of large vessel occlusion in acute 
ischaemic stroke (Project 7.6.1.). I had a substantial role in the conception and planning of this project, 
including writing the ethics proposal, coordination of the study group, development of the statistical 
analysis plan, and data collection. 
During the last year of my PhD, I was able to pursue a new research idea with the aim to improve 
identification of unstable carotid plaques by investigating protein expression patterns in 
endarterectomy specimens (Project 7.6.2.). For this project, I submitted a grant proposal to the Swiss 
Heart Foundation as main applicant. 
Throughout my PhD, I drafted and revised manuscripts, ethics proposals and one grant proposal with 
the help of my primary supervisor and the input from our co-authors. I regularly presented our work 
and our findings at national and international conferences and received four national awards.  
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9. Conclusion and closing remarks 
 
Our update of the Cochrane Review on carotid stenting versus endarterectomy for treatment of 
carotid stenosis yielded high-quality evidence for the comparison of short-term risk of stroke or death 
in patients with symptomatic carotid stenosis, which clearly favours endarterectomy over carotid 
stenting. Beyond 30 days after treatment, stenting is as effective in preventing recurrent stroke as 
endarterectomy. However, combining procedural safety and long-term efficacy in preventing 
recurrent stroke still favours endarterectomy over carotid stenting. For patients with asymptomatic 
carotid stenosis, the available evidence showed a strong trend towards endarterectomy showing a 
lower short-term risk of stroke or death. However, there was only moderate quality evidence and more 
data from ongoing randomised trials are needed. Concerning the durability of stenting in patients with 
asymptomatic carotid stenosis, only limited data are available and these do not yet allow any firm 
conclusions. 
In our second project, we identified complex vascular anatomy as an important predictor for cerebral 
ischaemia in patients with symptomatic carotid stenosis treated with stenting. Stenting should 
therefore be avoided in patients with symptomatic carotid stenosis and difficult configuration of the 
aortic arch or increased tortuosity of the internal carotid artery.  
Furthermore, we were able to show that the excess occurrence of stroke or death associated with 
stenting is limited to the day of treatment. This finding demonstrates the need to improve procedural 
safety of carotid stenting. It remains to be determined whether recent advances in stenting technology 
(new devices, direct carotid access, new protection systems) improve the safety of this procedure.  
Our analysis of temporal trends in procedural risks of stenting and endarterectomy revealed that the 
risk of stroke or death associated with carotid revascularisation procedures has decreased over time. 
The decline in stroke or death risk was particularly apparent in patients treated with endarterectomy. 
As stroke risk associated with carotid disease has also decreased, currently ongoing randomised trials 
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will ultimately answer the question whether patients with carotid stenosis who are at low or moderate 
risk of stroke still benefit from carotid revascularisation procedures.   
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